

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number
WO 03/077848 A2

(51) International Patent Classification⁷: **A61K**
(21) International Application Number: PCT/US03/07340
(22) International Filing Date: 10 March 2003 (10.03.2003)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
10/096,399 12 March 2002 (12.03.2002) US
(71) Applicant (*for all designated States except US*): **ISIS PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **KOLLER, Erich** [CH/US]; 2622 Lewis Lane, Carlsbad, CA 92008 (US). **SHAPARD, Peter, J.** [US/US]; 3828 Third Avenue, #5, San Diego, CA 92103 (US).

(74) Agents: **LICATA, Jane, Massey** et al.; Licata & Tyrrell P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: JAGGED 2 INHIBITORS FOR INDUCING APOPTOSIS

(57) Abstract: The present invention provides methods for inducing apoptosis and for treating conditions associated with insufficient apoptosis. These methods are based on the novel observation that inhibition of Jagged 2 induces apoptosis and causes cell death. Thus methods of use for Jagged 2 inhibitors are provided.



WO 03/077848 A2

JAGGED 2 INHIBITORS FOR INDUCING APOPTOSIS

5

FIELD OF THE INVENTION

The invention relates to prevention and treatment of diseases and conditions associated with insufficient
10 apoptosis. This is accomplished through use of inhibitors of Jagged 2. Use of Jagged 2 inhibitors for inducing apoptosis is also provided.

BACKGROUND OF THE INVENTION

15

Apoptosis, or programmed cell death, is a naturally occurring process that has been strongly conserved during evolution to prevent uncontrolled cell proliferation. This form of cell suicide plays a crucial role in ensuring
20 the development and maintenance of multicellular organisms by eliminating superfluous or unwanted cells. However, if this process becomes overstimulated, cell loss and degenerative disorders including neurological disorders such as Alzheimers, Parkinsons, ALS, retinitis pigmentosa
25 and blood cell disorders can result. Stimuli which can trigger apoptosis include growth factors such as tumor necrosis factor (TNF), Fas and transforming growth factor beta (TGF β), neurotransmitters, growth factor withdrawal, loss of extracellular matrix attachment and extreme
30 fluctuations in intracellular calcium levels (Afford and Randhawa, *Mol. Pathol.*, 2000, 53, 55-63).

Alternatively, insufficient apoptosis, triggered by a variety of stimuli including growth factors, extracellular matrix changes, CD40 ligand, viral gene products, neutral amino acids, zinc, estrogen and androgens, can contribute to the development of cancer, autoimmune disorders and viral infections (Afford and Randhawa, *Mol. Pathol.*, **2000**, 53, 55-63). Consequently, apoptosis is regulated under normal circumstances by the interaction of gene products that either induce or inhibit cell death and several gene products that modulate the apoptotic process have now been identified. In the prevention or treatment of conditions associated with or characterized by insufficient apoptosis, compounds which induce apoptosis are believed to be useful.

Notch signaling is an evolutionarily conserved mechanism used to control cell fates through local cell interactions. The gene encoding the original Notch receptor was discovered in *Drosophila* due to the fact that partial loss of function of the gene results in notches at the wing margin (Artavanis-Tsakonas et al., *Science*, **1999**, 284, 770-776). Genetic and molecular interaction studies have resulted in the identification of a number of proteins involved in the transmission of Notch signals. In *Drosophila*, two single-pass transmembrane proteins known as Delta and Serrate are Notch ligands within the core of the Notch signaling pathway (Artavanis-Tsakonas et al., *Science*, **1999**, 284, 770-776).

In vertebrates, the serrate gene is known as Jagged (also known as JAG) and was first isolated from a rat cDNA library. Lindsell, *Cell*, **1995**, 80, 909-917. The report of a second rat homolog gene termed Jagged 2 (Shawber et al.,

Dev. Biol., **1996**, 180, 370-376) was soon followed by the isolation of human Jagged 2 gene (Luo et al., *Mol. Cell Biol.*, **1997**, 17, 6057-6067).

The overall gene structure of human Jagged 2 is similar to that of human Jagged 1 which suggests that the two Jagged genes may have been evolutionarily derived from a duplication of an ancestor gene (Deng et al., *Genomics*, **2000**, 63, 133-138). However, Jagged 1 and Jagged 2 show both overlapping and unique patterns of expression in various tissues, indicating non-redundant roles for these two Notch ligands (Luo et al., *Mol. Cell Biol.*, **1997**, 17, 6057-6067). The Jagged 2 gene is located on chromosome 14q32, a region linked to the genetic disease known as Usher syndrome type Ia, a congenital sensory deafness associated with retinitis pigmentosa (Deng et al., *Genomics*, **2000**, 63, 133-138). The mouse Jagged 2 knockout phenotype includes cranial, facial, limb and thymic defects (Jiang et al., *Genes Dev.*, **1998**, 12, 1046-1057).

Human Jagged 2 appears to mediate control of differentiation events in mammalian muscle and to be involved in positive feedback control of expression of a group of genes encoding Notch1, Notch3 and Jagged 1 (Luo et al., *Mol. Cell Biol.*, **1997**, 17, 6057-6067). Constitutive activation of Notch1 results in delays human hematopoietic differentiation due to altered cell cycle kinetics (Carlesso et al., *Blood*, **1999**, 93, 838-848).

In addition to its role in cell differentiation, Notch signaling has been demonstrated to influence proliferation and apoptosis (Artavanis-Tsakonas et al., *Science*, **1999**, 284, 770-776). Notch1 was originally identified as a gene that is rearranged by a recurrent

chromosomal translocation associated with human T lymphoblastic leukemias (Ellisen et al., *Cell*, **1991**, 66, 649-661) and the existence of oncogenic forms of Notch2 have been documented (Aster et al., *J. Biol. Chem.*, **1997**, 272, 11336-11343). Notch1 activation in T cells has been shown to protect the cells from T cell receptor-mediated apoptosis (Jehn et al., *J. Immunol.*, **1999**, 162, 635-638). Thus, modulation of Jagged 2 expression may prove a useful method for treating cancer.

10 Inhibition of expression by antisense oligonucleotides has been demonstrated for Notch1 (Zimrin et al., *J. Biol. Chem.*, **1996**, 271, 32499-32502; Zine et al., *Development*, **2000**, 127, 3373-3383) and Jagged 1. United States patent number 6,004,924 (Ish-Horowicz et al.) discloses Serrate antisense nucleic acids, including Serrate 1 and Serrate 2.

It has now, surprisingly, been found, using both a caspase activity model and cell cycle analysis, that inhibition of Jagged 2 actually induces apoptosis. A number of well accepted chemotherapeutic drugs have previously been shown to induce apoptosis in a caspase-dependent manner accompanied by cell cycle disruption (Seimiya, H., et al., *J. Biol. Chem.*, **1997**, 272, 4631-4636; Simizu, S. et al., *J. Biol. Chem.*, **1998**, 273, 26900-26907).

SUMMARY OF THE INVENTION

It has now been discovered that inhibition of Jagged 2 induces apoptosis. Accordingly, methods for treating and preventing diseases and conditions associated with, or characterize by, insufficient apoptosis are provided.

According to one aspect of the invention, a method for treating a subject having a condition associated with

insufficient apoptosis is provided. The method includes administering to a subject in need of such treatment a Jagged 2 inhibitor in an amount effective to reduce Jagged 2 activity. Preferably, the subject is free of symptoms otherwise calling for treatment with the Jagged 2 inhibitor. In preferred embodiments, the Jagged 2 inhibitor is a small molecule compound, an inhibitory antibody, a peptide or peptide fragment, particularly a dominant negative Jagged 2 protein, an antisense nucleic acid, an inhibitory RNA such as a transfected and intracellularly expressed antisense RNA or a small interfering RNA; or a ribozyme or other catalytic nucleic acid. Preferably the Jagged 2 inhibitor is an antisense oligonucleotide. In other preferred embodiments, the Jagged 2 inhibitor is administered to a subject who has or is believed to be at risk for a condition associated with insufficient apoptosis. Preferably said condition is a hyperproliferative condition, more preferably cancer. According to another aspect of the invention, a pharmaceutical composition is provided. The pharmaceutical composition may include a Jagged 2 inhibitor and another chemotherapeutic agent, together in an amount effective for treating a condition associated with insufficient apoptosis. Preferably the chemotherapeutic agent is a conventional anti-cancer agent or an agent known to induce apoptosis. More preferably the chemotherapeutic agent works through a non-Jagged 2 mechanism. Preferred inhibitors and agents are well known in the art, with examples described hereinbelow.

According to still another aspect of the invention, a kit is provided. The kit includes a package housing a first container containing a Jagged 2 inhibitor, and instructions for using the Jagged 2 inhibitor in the treatment of a disease or condition associated with insufficient apoptosis. In certain embodiments, the kit

also includes a second container containing a chemotherapeutic agent, preferably a conventional anti-cancer agent or an agent known to induce apoptosis.

5 In another aspect of the invention, the use of the foregoing Jagged 2 inhibitors in the preparation of a medicament for the treatment of conditions associated with insufficient apoptosis, particularly hyperproliferative conditions including cancer, is provided.

10 These and other objects of the invention will be described in further detail in connection with the detailed description of the invention.

DETAILED DESCRIPTION OF THE INVENTION

Certain disorders are associated with an undesirable number of surviving cells, which continue to survive and/or proliferate when apoptosis is inhibited. These disorders include cancer (particularly follicular lymphomas, carcinomas associated with mutations in p53, and hormone-dependent tumors such as breast cancer, prostate cancer, and ovarian cancer), autoimmune disorders (such as systemic lupus erythematosus, immune-mediated glomerulonephritis), and viral infections (such as those caused by herpesviruses, poxviruses, and adenoviruses). Failure to remove autoimmune cells that arise during development or that develop as a result of somatic mutation during an immune response can result in autoimmune disease. Thus for these and other conditions associated with insufficient apoptosis, inhibitors of Jagged 2 are believed to be useful, as a result of the finding that Jagged 2 inhibitors can actually induce apoptosis. A Jagged 2 inhibitor, as used herein, is a compound which inhibits Jagged 2 activity, expression or levels. As used herein, "inhibit" may be partial or complete reduction in the amount or activity of Jagged 2 to a level below that found under normal physiological conditions if used prophylactically, or below the existing

15
20
25
30
35

conditions if used in treatment of an active or acute condition.

Compounds which are useful as Jagged 2 inhibitors include compounds which act on the Jagged 2 protein to directly inhibit Jagged 2 function or activity, as well as compounds which indirectly inhibit Jagged 2 by reducing amounts of Jagged 2, e.g., by reducing expression of the gene encoding Jagged 2 via interference with transcription, translation, or processing of the mRNA encoding Jagged 2. Inhibitors of Jagged 2 also include compounds which bind to Jagged 2 and inhibit its function, including its ability to serve as a ligand for Notch. Thus inhibitors of Jagged 2 include small molecule compounds, preferably organic small molecule compounds; inhibitory antibodies, peptides and peptide fragments, particularly Jagged 2 dominant negative peptides and fragments. Inhibitors of Jagged 2 also include compounds which inhibit the expression or reduce the levels of Jagged 2, including antisense nucleic acids, particularly antisense oligonucleotides, including peptide nucleic acids, morpholino compounds and other antisense compounds which bind by Watson-Crick base pairing with the Jagged 2 RNA target, ribozymes and other catalytic oligonucleotides, and inhibitory RNAs including transfected, intracellularly expressed antisense RNAs as well as small interfering RNAs (siRNA). Particularly preferred Jagged 2 inhibitors are antisense inhibitors of Jagged 2. These and other inhibitors of Jagged 2 can be used to prevent or decrease the effects of insufficient apoptosis mediated by Jagged 2.

The present invention employs inhibitors of Jagged 2 for use in inducing apoptosis, or for preventing and/or treating conditions associated with insufficient apoptosis. In a preferred embodiment, this is accomplished by providing antisense compounds which specifically

hybridize with one or more nucleic acids encoding Jagged 2. As used herein, the terms "target nucleic acid" and "nucleic acid encoding Jagged 2" encompass DNA encoding Jagged 2, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of Jagged 2. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is

a nucleic acid molecule encoding Jagged 2. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding Jagged 2, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA,

respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript

before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets.

It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

It is also known in the art that alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants". More specifically, "pre-mRNA variants" are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and extronic regions. Upon excision of one or more exon or intron regions or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants". Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as "alternative splice variants". If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant.

It is also known in the art that variants can be produced through the use of alternative signals to start or stop transcription and that pre-mRNAs and mRNAs can possess more than one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as "alternative start

variants" of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon are known as "alternative stop variants" of that pre-mRNA or mRNA. One specific type of alternative stop variant is the "polyA variant" in which the multiple transcripts produced result from the alternative selection of one of the "polyA stop signals" by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that

the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense and other compounds of the invention which hybridize to the target and inhibit expression of the target are identified through experimentation, and the sequences of these compounds are hereinbelow identified as preferred embodiments of the invention. The target sites to which these preferred sequences are complementary are hereinbelow referred to as "active sites" and are therefore preferred sites for targeting. Therefore another embodiment of the invention encompasses compounds which hybridize to these active sites. Examples of such compounds include antisense compounds, and oligonucleotides, including probes, primers, catalytic oligonucleotides such as ribozymes, and inhibitory RNAs including siRNAs and transfected vector-based antisense RNAs.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for

example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

For use in kits and diagnostics, the antisense
5 compounds of the present invention, either alone or in combination with other antisense compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed
10 within cells and tissues.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in
15 animals and man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that
20 can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of
25 ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions
30 which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of
35 nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described
5 below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those
10 comprising from about 12 to about 50 nucleobases. Antisense compounds include inhibitory RNAs, including intracellularly expressed transfected antisense RNAs, short interfering RNAs (siRNAs) which function through a gene silencing mechanism such as RNA interference (RNAi),
15 ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

As is known in the art, a nucleoside is a base-sugar
20 combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar
25 portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to
30 form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are
35 commonly referred to as forming the internucleoside

backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds
5 useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the
10 backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to
15 be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates
20 including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters,
25 selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted polarity
30 comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

35 Representative United States patents that teach the

preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are commonly owned with this application, and each
10 of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or
15 cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone
20 backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide
25 backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 30 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and
35 5,677,439, certain of which are commonly owned with this

application, and each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, **1991**, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$ [known as a methylene (methylimino) or MMI backbone], $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$ and $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$ [wherein the native phosphodiester backbone is represented as $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred

oligonucleotides comprise one of the following at the 2' position: OH; F;

O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other preferred

oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, **1995**, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminoethoxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, also described in examples hereinbelow.

A further preferred modification includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene (-CH₂-)_n group bridging the 2'

oxygen atom and the 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂), 2'-allyl (2'-CH₂-CH=CH₂), 2'-O-allyl (2'-O-CH₂-CH=CH₂) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide.

Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.

Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-

thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl ($-C\equiv C-CH_3$) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, **1990**, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, **1991**, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, **1993**. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include

5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyl-adenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase
5 nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, **1993**, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar
10 modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as
15 well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly
20 owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the
25 invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include conjugate groups covalently bound to
30 functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that

enhance the pharmacokinetic properties of oligomers. Typical conjugates groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed October 23, 1992 the entire disclosure of which is incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, **1989**, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1994**, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, **1992**, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1993**, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, **1992**, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, **1991**, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, 259, 327-330; Svinarchuk et al., *Biochimie*, **1993**, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, **1995**, 14,

969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-
5 oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, **1996**, 277, 923-937. Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbuta-
zone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-
10 pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodo-benzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepam, indo-
methicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.
15 Oligonucleotide-drug conjugates and their preparation are described in United States Patent Application 09/334,130 (filed June 15, 1999) which is incorporated herein by reference in its entirety.

Representative United States patents that teach the
20 preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439;
25 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098;
30 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is
35 herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides,

oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.:
5 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is
10 herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors
15 including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and
20 alkylated derivatives.

In other embodiments, the present invention provides use of Jagged 2 inhibitors which are dominant negative Jagged 2 polypeptides or fragments thereof. A dominant negative polypeptide is an inactive variant of a protein
25 which competes with or otherwise interferes with the active protein, reducing the function or effect of the normal active protein. In the case of Jagged 2, one such function is the ability to serve as a ligand for Notch. One of ordinary skill in the art can use standard and
30 accepted mutagenesis techniques to generate dominant negative polypeptides. For example, one of ordinary skill in the art can use the nucleotide sequence of Jagged 2 along with standard techniques for site-directed mutagenesis, scanning mutagenesis, partial deletions,
35 truncations, and other such methods known in the art. For

examples, see Sambrook et al., *Molecular Cloning : A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, NY, 1989, pp. 15.3-15.113. Dominant negatives of the Drosophila homolog of Jagged are known.

- 5 Sun et al., *Development*, **1996**, 122, 2465-2474.

In further embodiments, the present invention provides use of antibodies or fragments thereof which selectively bind to Jagged 2 and in so doing, selectively inhibit or interfere with the activity of the Jagged 2
10 polypeptide. Standard methods for preparation of monoclonal and polyclonal antibodies and active fragments thereof are well known in the art. Antibody fragments, particularly Fab fragments and other fragments which retain epitope-binding capacity and specificity are also
15 well known, as are chimeric antibodies, such as "humanized" antibodies, in which structural (not determining specificity for antigen) regions of the antibody are replaced with analogous or similar regions from another species. Thus antibodies generated in mice
20 can be "humanized" to reduce negative effects which may occur upon administration to human subjects. Chimeric antibodies are now accepted therapeutic modalities with several now on the market. The present invention therefore comprehends use of antibody inhibitors of Jagged
25 2 which include F(ab')₂, Fab, Fv and Fd antibody fragments, chimeric antibodies in which one or more regions have been replaced by homologous human or non-human portions, and single chain antibodies. Antibodies to human Jagged 2 are known (Gray et al., *Am. J. Pathol.*, **1999**, 154, 785-94) and
30 at least one Jagged 2 antibody is commercially available (Santa Cruz Biotechnology, CA, Cat. No. sc-8157).

Small molecule inhibitors are useful for elucidating cellular processes. They are more stable than peptides and are often cell-permeable (Degterev et al., *Nature Cell Biol.*, **2001**, 3, 173-182). Libraries of small organic
35

molecules can be obtained commercially (ChemBridge Corp., San Diego CA; LION Biosciences (formerly Trega), San Diego CA) or can be prepared according to standard methods (Thompson, L.A. and J.A. Ellman, *Chem. Rev.*, **1996**, 96, 555-600). An appropriate screen or assay for inhibitors of the desired molecule is key to finding inhibitors with the desired selectivity and specificity. In vitro Notch signaling assays are known (Bruckner et al., *Nature*, **2000**, 406, 411-415). Small molecule inhibitors of Jagged 2 are believed to be useful in the methods of the present invention.

For use in the methods of the invention, Jagged 2 inhibitors may be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

For use in the methods of the invention, Jagged 2 inhibitors encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue of said Jagged 2 inhibitor. Accordingly, for example, the

disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of these inhibitors, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

5 The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the
10 oligonucleotide inhibitors of Jagged 2 are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 and U.S. 5,770,713 to Imbach et al.

15 The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

20 Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are
25 N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, **1977**, 66, 1-19). The base addition salts of said acidic
30 compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional
35 manner. The free acid forms differ from their respective

salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylemaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of

compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

Use of Jagged 2 inhibitors in the methods of the invention may be useful therapeutically as well as prophylactically, e.g., to prevent or delay conditions associated with Jagged 2 mediated insufficiency of apoptosis, for example.

The methods of the present invention also include use of pharmaceutical compositions and formulations which include Jagged 2 inhibitors. The pharmaceutical compositions may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous

membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or
5 parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl
10 modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories,
15 sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Preferred topical formulations include those in which the Jagged 2
20 inhibitors are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine,
25 dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). Inhibitors may
30 be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, inhibitors may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters include but are not limited arachidonic acid, oleic
35 acid, eicosanoic acid, lauric acid, caprylic acid, capric

33

acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an
5 acylcholine, or a C₁₋₁₀ alkyl ester (e.g. isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof. Topical formulations are described in detail in United States patent application 09/315,298 filed on May 20, 1999 which
10 is incorporated herein by reference in its entirety.

Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets,
15 tablets or minitables. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Preferred oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers
20 surfactants and chelators. Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic
25 acid, glucolic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate, sodium glycodihydrofusidate,. Preferred fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric
30 acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a
35 diglyceride or a pharmaceutically acceptable salt thereof

(e.g. sodium). Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Inhibitors for use in methods of the invention may be delivered orally in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Particularly preferred complexing agents for oligonucleotides include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylamino-methylethylene P(TDAE), polyaminostyrene (e.g. p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcyanoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for oligonucleotides and their preparation are described in detail in United States applications 08/886,829 (filed July 1, 1997), 09/108,673 (filed July 1, 1998), 09/256,515 (filed February 23, 1999), 09/082,624 (filed May 21, 1998) and 09/315,298 (filed May 20, 1999) each of which is incorporated herein by reference in their entirety.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not
5 limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a
10 variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

Pharmaceutical formulations, which may conveniently be presented in unit dosage form, may be prepared
15 according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately
20 bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions may be formulated into any of many possible dosage forms such as, but not limited to,
25 tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including,
30 for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as
35 foams. Pharmaceutical foams include formulations such as,

but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

Emulsions

10 Compositions for use in the present method may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. (Idson, in *Pharmaceutical Dosage Forms*,
15 Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*,
20 Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, **1985**, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases
25 intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a
30 water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to

the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed.

Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature

(Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., **1988**, volume 1, p. 199).

5 Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and
10 is a valuable tool in categorizing and selecting surfactants in the preparation of formulations.

Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel
15 Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic
20 properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous
25 preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids
30 such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants,
35 hydrophilic colloids, preservatives and antioxidants

(Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature

(Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

The compositions for use in the present methods are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., **1989**, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water,

surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric
5 packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, **1985**, p. 271).

The phenomenological approach utilizing phase
10 diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245;
15 Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of
20 thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers,
25 polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprates (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol
30 decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered
35 film because of the void space generated among surfactant

molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, **1994**, *11*, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, **1993**, *13*, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, **1994**, *11*, 1385; Ho et al., *J. Pharm. Sci.*, **1996**, *85*, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal

delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic
5 absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides, nucleic acids and other inhibitors within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

10 Microemulsions may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of
15 the present invention. Penetration enhancers used in microemulsions may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier*
20 *Systems*, **1991**, p. 92). Each of these classes has been discussed above.

Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for
25 the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present
30 invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material
35 and an aqueous interior. The aqueous portion contains the

composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by
5 macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable
10 to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of
15 water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245).
20 Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the
25 liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the
30 active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over
35 other formulations. Such advantages include reduced side-

effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic
5 and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have
10 been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact
15 with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their
20 contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, **1987**, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly
25 charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the
30 exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, **1992**, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for
35 example, can be formed from dimyristoyl

phosphatidylcholine (DMPC) or dipalmitoyl
phosphatidylcholine (DPPC). Anionic liposome compositions
generally are formed from dimyristoyl
phosphatidylglycerol, while anionic fusogenic liposomes
5 are formed primarily from dioleoyl
phosphatidylethanolamine (DOPE). Another type of
liposomal composition is formed from phosphatidylcholine
(PC) such as, for example, soybean PC, and egg PC.
Another type is formed from mixtures of phospholipid
10 and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of
liposomal drug formulations to the skin. Application of
liposomes containing interferon to guinea pig skin
resulted in a reduction of skin herpes sores while
15 delivery of interferon via other means (e.g. as a solution
or as an emulsion) were ineffective (Weiner *et al.*,
Journal of Drug Targeting, **1992**, 2, 405-410). Further, an
additional study tested the efficacy of interferon
administered as part of a liposomal formulation to the
20 administration of interferon using an aqueous system, and
concluded that the liposomal formulation was superior to
aqueous administration (du Plessis *et al.*, *Antiviral
Research*, **1992**, 18, 259-265).

Non-ionic liposomal systems have also been examined
25 to determine their utility in the delivery of drugs to the
skin, in particular systems comprising non-ionic
surfactant and cholesterol. Non-ionic liposomal
formulations comprising Novasome™ I (glyceryl
dilaurate/cholesterol/polyoxyethylene-10-stearyl ether)
30 and Novasome™ II (glyceryl distearate/
cholesterol/polyoxyethylene-10-stearyl ether) were used to
deliver cyclosporin-A into the dermis of mouse skin.
Results indicated that such non-ionic liposomal systems
were effective in facilitating the deposition of

cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, **1994**, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1} , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, **1987**, 223, 42; Wu et al., *Cancer Research*, **1993**, 53, 3765). Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, **1987**, 507, 64) reported the ability of monosialoganglioside G_{M1} , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, **1988**, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO

97/13499 (Lim et al.).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, **1980**, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety. Illum et al. (*FEBS Lett.*, **1984**, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov et al. (*FEBS Lett.*, **1990**, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, **1990**, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent

Nos. 5,540,935 (Miyazaki *et al.*) and 5,556,948 (Tagawa *et al.*) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic
5 acids are known in the art. WO 96/40062 to Thierry *et al.* discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa *et al.* discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an
10 antisense RNA. U.S. Patent No. 5,665,710 to Rahman *et al.* describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love *et al.* discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

15 Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to
20 penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without
25 fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated
30 delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and
35 liposomes. The most common way of classifying and ranking

the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include

quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

5 If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

10 The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, **1988**, p. 285).

Penetration Enhancers

15 Compositions for use in the methods of the invention may contain various penetration enhancers to effect the efficient delivery of inhibitors, particularly oligonucleotide inhibitors, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has
20 been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of
25 lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, *i.e.*, surfactants, fatty acids, bile salts, chelating agents, and non-chelating
30 non-surfactants (Lee *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present
35 invention, surfactants (or "surface-active agents") are

chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of
5 oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic*
10 *Drug Carrier Systems*, **1991**, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, **1988**, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include,
15 for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-
20 monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and diglycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et
25 al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, **1992**, 44, 651-654).

Bile salts: The physiological role of bile includes
30 the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, **1996**, pp. 934-935). Various natural bile salts, and their synthetic

derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, 5 for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium 15 glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, **1990**, pages 782-783; 20 Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, **1992**, 263, 25; Yamashita et al., *J. Pharm. Sci.*, **1990**, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as 25 compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration 30 enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, **1993**, 618, 315-

339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), *N*-acyl derivatives of collagen, laureth-9 and *N*-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; Buur et al., *J. Control Rel.*, **1990**, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, **1987**, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including

glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Carriers

5 Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (*i.e.*, does not possess biological activity *per se*) but is
10 recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid
15 and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic
20 acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid
25 (Miyao *et al.*, *Antisense Res. Dev.*, **1995**, 5, 115-121; Takakura *et al.*, *Antisense & Nucl. Acid Drug Dev.*, **1996**, 6, 177-183).

Excipients

In contrast to a carrier compound, a "pharmaceutical
30 carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more compounds to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in
35 mind, so as to provide for the desired bulk, consistency,

etc., when combined with an inhibitor and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids or other inhibitors can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with the inhibitor can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.
Other Components

The compositions for use in the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions or kits containing (a) one or more Jagged 2 inhibitors and (b) one or more other chemotherapeutic agents. Examples of such chemotherapeutic

agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-
5 chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea,
10 nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptapurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramidate, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX),
15 colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin, camptothecin, aphidicolin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed. **1987**, pp. 1206-
20 1228, Berkow et al., eds., Rahway, N.J. When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and
25 oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and
30 corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds. **1987**, Rahway,
35 N.J., pages 2499-2506 and 46-49, respectively). Other

chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds, including two inhibitors of Jagged 2, may be used together or sequentially. In some embodiments an inhibitor of Jagged 2 is administered in combination with (simultaneously or sequentially) another agent for inducing apoptosis where said agent is not a Jagged 2 inhibitor. Examples of such compounds include taxol, cisplatin, etoposide, gemcitabine, camptothecin, aphidicolin and 5-fluorouracil.

10 The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several
15 days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages,
20 dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual inhibitors, and can generally be estimated based on EC_{50} s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to
25 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily
30 fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the inhibitors is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body
35 weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

EXAMPLES

Example 1

Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2'-alkoxy amidites

2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA). Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., *Nucleic Acids Research*, **1993**, *21*, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA).

2'-Fluoro amidites

2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, **1993**, *36*, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by

61

modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S_N2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropyldisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain

the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods
5 of Martin, P., *Helvetica Chimica Acta*, **1995**, 78, 486-504.

2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279
10 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened
15 solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into
20 fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated
25 with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C).

30 **2'-O-Methoxyethyl-5-methyluridine**

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After

heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with
5 acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior
10 to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine
15

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and
20 the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70%
25 product. The solvent was evaporated and triturated with CH₃CN (200 mL). The residue was dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, filtered and evaporated. 275 g of residue was
30 obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give

a total yield of 183 g (57%).

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl₃ (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl₃. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl₃ was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was

65

stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was
5 washed with 1x300 mL of NaHCO₃ and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

10 **2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH₄OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was
15 evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel.

MeOH (400 mL) saturated with NH₃ gas was added and the vessel heated to 100°C for 2 hours (TLC showed complete
20 conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

25 **N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with
30 stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl₃ (700 mL) and extracted with saturated NaHCO₃ (2x300 mL) and saturated

66

NaCl (2x300 mL), dried over MgSO_4 and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/hexane (1:1) containing 0.5% Et_3NH as the eluting solvent. The pure product fractions
5 were evaporated to give 90 g (90%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH_2Cl_2 (1
10 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction
15 mixture was extracted with saturated NaHCO_3 (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH_2Cl_2 (300 mL), and the extracts were combined, dried over MgSO_4 and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column
20 using EtOAc/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites

25 **2'-(Dimethylaminooxyethoxy) nucleoside amidites**

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine
30 nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine

O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine
5 (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. *tert*-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was
10 stirred for 16 h at ambient temperature. TLC (R_f 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine
15 (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by
20 filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

25 In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-tert-
30 Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure <

100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g.

The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylldiphenylsilyl-5-methyluridine

5'-O-tert-Butylldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over P₂O₅ under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the

completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidooxy)ethyl]-5'-*t*-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidooxy)ethyl]-5'-*t*-butyldiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH₂Cl₂ and the combined organic phase was washed with water, brine and dried over anhydrous Na₂SO₄. The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%).

5'-O-*tert*-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium *p*-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC

(5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na₂SO₄, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO₃ (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH₂Cl₂ to get 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

2'-O-(dimethylaminoxyethyl)-5-methyluridine

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH₂Cl₂ to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine

2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over P₂O₅ under high vacuum overnight

at 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH₂Cl₂ (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P₂O₅ under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N¹,N¹-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO₃ (40mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

2'-(Aminooxyethoxy) nucleoside amidites

2'-(Aminooxyethoxy) nucleoside amidites [also known

in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

- 5 **N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside
10 may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to
15 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-
20 diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-hydroxyethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-
25 hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-([2-phthalamidoxy]ethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].
30 **2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites**

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, or 2'-DMAEOE nucleoside

amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g,
5 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O²-,2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed,
10 placed in an oil bath and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous
15 layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent.
20 As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

25 To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and
30 extracted with CH₂Cl₂ (2x200 mL). The combined CH₂Cl₂ layers are washed with saturated NaHCO₃ solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using MeOH:CH₂Cl₂:Et₃N (20:1, v/v, with

1% triethylamine) gives the title compound.

5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

5 Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH₂Cl₂ (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

Example 2

15 Oligonucleotide synthesis

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

20 Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by

reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

5 Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902
10 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference. 3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

15 Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both
20 herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedi-
25 methylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligo-
30 nucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

35 Formacetal and thioformacetal linked oligonucleosides

are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated
5 by reference.

Example 4

PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to
10 in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, **1996**, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

15 Example 5

Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type
20 wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first
25 type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric

Phosphorothioate Oligonucleotides

30 Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated

synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphor-
 amidite for the DNA portion and 5'-dimethoxytrityl-2'-O-
 methyl-3'-O-phosphoramidite for 5' and 3' wings. The
 standard synthesis cycle is modified by increasing the
 5 wait step after the delivery of tetrazole and base to 600
 s repeated four times for RNA and twice for 2'-O-methyl.
 The fully protected oligonucleotide is cleaved from the
 support and the phosphate group is deprotected in 3:1
 ammonia/ethanol at room temperature overnight then
 10 lyophilized to dryness. Treatment in methanolic ammonia
 for 24 hrs at room temperature is then done to deprotect
 all bases and sample was again lyophilized to dryness.
 The pellet is resuspended in 1M TBAF in THF for 24 hrs at
 room temperature to deprotect the 2' positions. The
 15 reaction is then quenched with 1M TEAA and the sample is
 then reduced to 1/2 volume by rotovac before being
 desalted on a G25 size exclusion column. The oligo
 recovered is then analyzed spectrophotometrically for
 yield and for purity by capillary electrophoresis and by
 20 mass spectrometry.

**[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-
 (Methoxyethyl)] Chimeric Phosphorothioate
 Oligonucleotides**

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxy-
 25 ethyl)] chimeric phosphorothioate oligonucleotides were
 prepared as per the procedure above for the 2'-O-methyl
 chimeric oligonucleotide, with the substitution of 2'-O-
 (methoxyethyl) amidites for the 2'-O-methyl amidites.

**[2'-O-(2-Methoxyethyl) Phosphodiester]--[2'-deoxy
 30 Phosphorothioate]--[2'-O-(2-Methoxyethyl)
 Phosphodiester] Chimeric Oligonucleotides**

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy
 phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester]
 chimeric oligonucleotides are prepared as per the above

procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dithiolane-2-one 1,1-dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

Example 6

15 Oligonucleotide Isolation

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by ³¹P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7

Oligonucleotide Synthesis - 96 Well Plate Format

Oligonucleotides were synthesized via solid phase

P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by
5 oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzothiole-3-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites
10 were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyl-diisopropyl phosphoramidites.
15 Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature ($55-60^\circ\text{C}$) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all
20 analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8

Oligonucleotide Analysis - 96 Well Plate Format

The concentration of oligonucleotide in each well was
25 assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE
30 apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were

judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

Example 9

Cell culture and oligonucleotide treatment

5 The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The
10 following 5 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis,
15 Ribonuclease protection assays, or RT-PCR.

T-24 cells:

 The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were
20 routinely cultured in complete McCoy's 5A basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum ((Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA).
25 Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

 For Northern blotting or other analysis, cells may be
30 seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

 The human lung carcinoma cell line A549 was obtained
35 from the American Type Culture Collection (ATCC)

(Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville, MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville, MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville, MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville, MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

Treatment with antisense compounds:

When cells reached 70% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 100 μ L OPTI-MEMTM-1 reduced-serum medium (Invitrogen Corporation, Carlsbad, CA) and then treated with 130 μ L of OPTI-MEMTM-1 containing 3.75 μ g/mL LIPOFECTINTM (Invitrogen Corporation, Carlsbad, CA) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control

5 oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is ISIS 13920, **TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-

10 ras. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCCAAGGA**, SEQ ID NO: 2, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of

15 positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not

20 achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that

25 particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

Example 10

Analysis of oligonucleotide inhibition of Jagged 2 expression

30 Antisense modulation of Jagged 2 expression can be assayed in a variety of ways known in the art. For example, Jagged 2 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time

quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. The preferred method of RNA analysis of the present invention is the use of total cellular RNA as described in other
5 examples herein. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., **1993**. Northern blot analysis is routine in the art and is taught in, for
10 example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., **1996**. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from
15 PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.

Protein levels of Jagged 2 can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis
20 (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to Jagged 2 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional
25 antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., **1997**. Preparation of monoclonal antibodies is taught in,
30 for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., **1997**.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al.,

Current Protocols in Molecular Biology, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., **1998**. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current*
5 *Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., **1997**. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp.
10 11.2.1-11.2.22, John Wiley & Sons, Inc., **1991**.

Example 11

Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, **1996**, 42, 1758-1764. Other methods for
15 poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., **1993**. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was
20 washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was
25 transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper
30 towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate

was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

5 **Example 12**

Total RNA Isolation

Total RNA was isolated using an RNEASY 96™ kit and
uffers purchased from Qiagen Inc. (Valencia, CA) following
the manufacturer's recommended procedures. Briefly, for
10 cells grown on 96-well plates, growth medium was removed
from the cells and each well was washed with 200 µL cold
PBS. 150 µL Buffer RLT was added to each well and the
plate vigorously agitated for 20 seconds. 150 µL of 70%
ethanol was then added to each well and the contents mixed
15 by pipetting three times up and down. The samples were
then transferred to the RNEASY 96™ well plate attached to
a QIAVAC™ manifold fitted with a waste collection tray and
attached to a vacuum source. Vacuum was applied for 1
minute. 500 µL of Buffer RW1 was added to each well of
20 the RNEASY 96™ plate and incubated for 15 minutes and the
vacuum was again applied for 1 minute. An additional 500
µL of Buffer RW1 was added to each well of the RNEASY 96™
plate and the vacuum was applied for 2 minutes. 1 mL of
Buffer RPE was then added to each well of the RNEASY 96™
25 plate and the vacuum applied for a period of 90 seconds.
The Buffer RPE wash was then repeated and the vacuum was
applied for an additional 3 minutes. The plate was then
removed from the QIAVAC™ manifold and blotted dry on paper
towels. The plate was then re-attached to the QIAVAC™
30 manifold fitted with a collection tube rack containing 1.2
mL collection tubes. RNA was then eluted by pipetting 170
µL water into each well, incubating 1 minute, and then

applying the vacuum for 3 minutes.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Example 13

Real-time Quantitative PCR Analysis of Jagged 2 mRNA

10 Levels

Quantitation of Jagged 2 mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., FAM, obtained from either Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can

be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

PCR reagents were obtained from Invitrogen, Carlsbad,

CA. RT-PCR reactions were carried out by adding 20 μ L PCR cocktail (2.5x PCR buffer (-MgCl₂), 6.6 mM MgCl₂, 375 μ M each of dATP, dCTP, dGTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNase inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5x ROX dye) to 96 well plates containing 30 μ L total RNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreen™ are taught in Jones, L.J., et al, Analytical Biochemistry, 1998, 265, 368-374.

In this assay, 170 μ L of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:350 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30 μ L purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 480nm and emission at 520nm.

Probes and primers to human Jagged 2 were designed to hybridize to a human Jagged 2 sequence, using published sequence information (GenBank accession number NM_002226.1, incorporated herein as SEQ ID NO:3). For

human Jagged 2 the PCR primers were:

forward primer: CCCAGGGCTTCTCCGG (SEQ ID NO: 4)

reverse primer: AATAGTCACCCCTCCAGGTTATAGCAG (SEQ ID NO: 5)

and the PCR probe was: FAM-TGGATGTCGACCTTTGTGAGCCAAGC-

5 TAMRA

(SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

For human GAPDH the PCR primers were:

10 forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 7)

reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 8) and the

PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ

ID NO: 9) where JOE (PE-Applied Biosystems, Foster City,

CA) is the fluorescent reporter dye) and TAMRA (PE-Applied

15 Biosystems, Foster City, CA) is the quencher dye.

Example 14

Northern blot analysis of Jagged 2 mRNA levels

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's recommendations for stringent

20

25

30

conditions.

To detect human Jagged 2, a human Jagged 2 specific probe was prepared by PCR using the forward primer CCCAGGGCTTCTCCGG (SEQ ID NO: 4) and the reverse primer AATAGTCACCCTCCAGGTTATAGCAG (SEQ ID NO: 5). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGERTM and IMAGEQUANTTM Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

Example 15

Antisense inhibition of human Jagged 2 expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human Jagged 2 RNA, using published sequences (GenBank accession number NM_002226.1, incorporated herein as SEQ ID NO: 3, GenBank accession number AF029778.1, incorporated herein as SEQ ID NO: 10, a genomic sequence of Jagged 2 represented by residues 104001-133000 of GenBank accession number AF111170.3, incorporated herein as SEQ ID NO: 11, and GenBank accession number BE674071.1, incorporated herein as SEQ ID NO: 12). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and

91

3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human Jagged 2 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 1

Inhibition of human Jagged 2 mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
148702	3'UTR	3	4647	Tacaaaaatgcactttcacg	79	13
148703	3'UTR	3	4698	tggcattattcaatcaaata	0	14
148704	5'UTR	10	2	gcgcacctgcatatgcatga	10	15
148705	Coding	10	475	gaaatagcccatgggcccgcg	74	16
148706	Coding	10	487	cagctgcagctcgaaatagc	62	17
148707	Coding	10	497	gcagcgcgctcagctgcagc	63	18
148708	Coding	10	518	gcagctccccgttcacgttc	33	19
148709	Coding	10	523	gctcagcagctccccgttca	67	20
148710	Coding	10	621	tgggtactccttaaggcacac	74	21
148711	Coding	10	631	caccttggcctgggtactcct	72	22
148712	Coding	10	658	gccgtagctgcagggccccc	65	23
148713	Coding	10	702	ggcaggtagaaggagttgcc	49	24
148714	Coding	10	775	gacgaggcccgggtcctggt	64	25
148715	Coding	10	843	ttgtcccagctcccaggcctc	92	26
148716	Coding	10	927	aggctcttccagcggtcctc	63	27
148717	Coding	10	937	gctgaagtgcaggctcttcc	61	28
148718	Coding	10	947	ccacgtggccgctgaagtgc	54	29
148719	Coding	10	1023	ggccggcagaacttggtgca	30	30
148720	Coding	10	1068	ttgccgtactggtcgcaggt	79	31
148721	Coding	10	1078	gcaggccttggtgccgtact	63	32
148722	Coding	10	1093	catccagccgtccatgcagg	84	33
148723	Coding	10	1149	cccccgtagagcaaattaca	71	34
148724	Coding	10	1183	gtagctgcacctgcactccc	84	35
148725	Coding	10	1269	cagttgcactgccagggctc	85	36
148726	Coding	10	1279	gttggtctcacagttgcact	64	37
148727	Coding	10	1287	ccgccccagttggtctcaca	77	38
148728	Coding	10	1292	gcaggccgccccagttggtc	23	39
148729	Coding	10	1297	acagagcaggccgccccagt	72	40
148730	Coding	10	1302	ttgtcacagagcaggccgcc	81	41
148731	Coding	10	1311	ttcaggtctttgtcacagag	74	42
148732	Coding	10	1321	gccacagtagttcaggtctt	60	43

148733	Coding	10	1331	gggtgggtggctgccacagtag	49	44
148734	Coding	10	1443	gaggtgcagggcgtgctcagc	63	45
148735	Coding	10	1672	cccttcacactcattggcgt	62	46
148736	Coding	10	1707	agggtttttgcaagaaaaagc	52	47
148737	Coding	10	1727	cacagtaatagccgccaatc	80	48
148738	Coding	10	1753	gatgcccttccagcccggga	75	49
148739	Coding	10	1810	gcaggtgcccccatgctgac	80	50
148740	Coding	10	1820	ccaggtccttgcaggtgccc	88	51
148741	Coding	10	1845	gggcacacacactggtaccc	71	52
148742	Coding	10	1902	gggctgctggcacacttgctc	88	53
148743	Coding	10	2100	gagcagttcttgccaccaa	85	54
148744	Coding	10	2154	ccgcagccatcgatcactct	93	55
148745	Coding	10	2334	gtgccccattgcggcaggg	73	56
148746	Coding	10	2474	agaagtcattgaccaggtcg	77	57
148747	Coding	10	2480	cacagtagaagtcattgacc	79	58
148748	Coding	10	2520	cgtgagtggcaggtcttgcc	68	59
148749	Coding	10	2530	ctggaactcgcgtgagtggc	56	60
148750	Coding	10	2556	ccgttgctgcaggtgtaggc	72	61
148751	Coding	10	2565	caggtgccaccggttgctgca	75	62
148752	Coding	10	2570	cgtagcaggtgccaccggtg	80	63
148753	Coding	10	2658	ttgggcaggcagctgctggt	64	64
148754	Coding	10	2770	agggttgccagtcgttggtat	50	65
148755	Coding	10	2824	gcagcggaaccagttgacgc	75	66
148756	Coding	10	2901	ccgtaggcacagggcgagga	78	67
148757	Coding	10	2925	ttgatctcatccacacacgt	80	68
148758	Coding	10	2949	gggtgggcagctacagcgata	75	69
148759	Coding	10	3061	gcagctggtgcagctctcca	0	70
148760	Coding	10	3071	ccaggcagcggcagctgttg	71	71
148761	Coding	10	3504	ctgctgtcaggcaggtccct	48	72
148762	Coding	10	3514	ctggatcaggctgctgtcag	61	73
148763	Coding	10	3597	tccaccttgacctcggtgac	69	74
148764	Coding	10	4059	gcgcgggttgctccactttggg	59	75
148765	Stop Codon	10	4104	ccctactccttgccggcgta	80	76
148766	3'UTR	10	4156	gacggcatggctcccaccga	75	77
148767	3'UTR	10	4274	gaataatttatacaagggtta	62	78
148768	3'UTR	10	4306	aatactccattgttttcagc	0	79
148769	3'UTR	10	4359	tcatacagcgagtgccacgc	74	80
148770	3'UTR	10	4378	caccctttgctctctccttt	67	81
148771	3'UTR	10	4492	caccggcactttggcctgga	64	82
148772	3'UTR	10	4538	gggtcccaccaacagccatg	83	83
148773	3'UTR	10	4845	gaagggcacttctgaaagca	56	84
148774	3'UTR	10	4928	acagttccgagggttctgtg	20	85
148775	Intron 5	11	15219	ctggctggatccccacact	83	86
148776	Intron 5	11	17034	gggagcactcctggctctgc	38	87
148777	Exon: Intron Junction	11	18740	ccatactgactgatatggca	78	88
148778	Intron: Exon Junction	11	20082	cgacatccacctgcaggggtg	70	89
148779	3'UTR	12	242	tggcaggccccgactcaaca	69	90

As shown in Table 1, SEQ ID NOs 13, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 71, 72, 73, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 86, 88, 89 and 90 demonstrated at least 40% inhibition of human Jagged 2 expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "active sites" and are therefore preferred sites for targeting by compounds of the present invention.

Example 16

Western blot analysis of Jagged 2 protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to Jagged 2 is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

Example 17

Caspase assay

With specific inhibitors of Jagged 2 now available, it is possible to examine the role that Jagged 2 plays in cancer.

Programmed cell death or apoptosis involves the activation of proteases, a family of intracellular proteases, through a cascade which leads to the cleavage of a select set of proteins. The caspase family contains

at least 14 caspases, with differing substrate preferences. The caspase activity assay uses a DEVD peptide to detect activated caspases in cell culture samples. The peptide is labeled with a fluorescent molecule, 7-amino-4-trifluoromethyl coumarin (AFC).
5 Activated caspases cleave the DEVD peptide resulting in a fluorescence shift of the AFC. Increased fluorescence is indicative of increased caspase activity. The chemotherapeutic drugs taxol, cisplatin, etoposide,
10 gemcitabine, camptothecin, aphidicolin and 5-fluorouracil all have been shown to induce apoptosis in a caspase-dependent manner.

Methods: The effect of the Jagged 2 inhibitor was examined in normal human mammary epithelial cells (HMECs) as well
15 as in two breast carcinoma cell lines, MCF7 and T47D, obtained from the American Type Culture Collection (Manassas VA). The latter two cell lines express similar genes but MCF7 cells express the tumor suppressor p53, while T47D cells are deficient in p53. MCF-7 cells were
20 routinely cultured in DMEM low glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. T47D cells
25 were cultured in Gibco DMEM High glucose media supplemented with 10% FBS.

Cells were plated at 10,000 cells per well for HMEC cells or 20,000 cells per well for MCF-7 and T47D cells, and allowed to attach to wells overnight. Plates used were
30 96 well Costar plate 1603 (black sides, transparent bottom). DMEM high glucose medium, with and without phenol red, were obtained from Invitrogen (San Diego CA). MEGM medium, with and without phenol red, were obtained from Biowhittaker (Walkersville MD). The caspase-3 activity
35 assay kit was obtained from Calbiochem (Cat. #HTS02).

Before adding to cells, the oligonucleotide cocktail was mixed thoroughly and incubated for 0.5 hrs. The oligonucleotide [the Jagged 2 antisense oligonucleotide ISIS 148715 (SEQ ID NO: 26) or the mixed sequence 20mer negative oligonucleotide control, ISIS 29848 (NNNNNNNNNNNNNNNNNNNNNN; SEQ ID NO:91) or the lipofectin only vehicle control was added (generally from a 3 μ M stock of oligonucleotide) to a final concentration of 200nM with 6 μ g/ml Lipofectin. The medium was removed from the plates and the plates were tapped on sterile gauze. Each well was washed in 150 μ l of PBS (150 μ L HBSS for HMEC cells). The wash buffer in each well was replaced with 100 μ L of the oligonucleotide/Opti-MEM/lipofectin cocktail (this was T=0 for oligonucleotide treatment). The plates were incubated for 4 hours at 37° C, after which the medium was dumped and the plate was tapped on sterile gauze. 100 μ l of full growth medium without phenol red was added to each well. After 48 hours, 50 μ l of oncogene buffer (provided with Calbiochem kit) with 10 μ M DTT was added to each well. 20 μ l of oncogene substrate (DEVD-AFC) was added to each well. The plates were read at 400+/-25nm excitation and 508+/-20nm emission at t=0 and t=3 time points. The t=0 x(0.8) time point was subtracted from the from the t=3 time point, and the data are shown as percent of lipofectin-only treated cells.

It was thus demonstrated that inhibitors of Jagged 2 induces caspase activity in all three cell lines tested. The Jagged 2 inhibitor ISIS 148715 caused roughly a 78% reduction of Jagged 2 RNA and approximately a 5.5 fold increase in fluorescence (indicating apoptosis) when administered to HMEC cells at a 200 nM concentration. In MCF7 cells, this Jagged 2 inhibitor reduced Jagged 2 RNA levels by approximately 50% and increased fluorescence

(indicating apoptosis) by approximately 3.4 fold (200 nM concentration). Similarly, in T47D cells, Jagged 2 RNA was decreased by approximately 75% and increased fluorescence (indicating apoptosis) by 8 fold (200 nM dose of ISIS 148715). A second Jagged 2 inhibitor, ISIS 148744 (SEQ ID NO: 55), reduced Jagged 2 RNA to a slightly lesser extent (approx. 43% reduction) than did ISIS 148715, but also increased apoptosis by approximately 2.5 fold in MCF7 cells and 3.5 fold in T47D cells. Interestingly, ISIS 148744 did not inhibit apoptosis in the normal HMEC cells, but only in the two cancer cell lines.

Example 18

Cell cycle analysis

Cell cycle regulation is the basis for various cancer therapies. Under some circumstances normal cells undergo growth arrest, while transformed cells undergo apoptosis and this difference can be used to protect normal cells against death caused by chemotherapeutic drugs. Disruption of cell cycle checkpoints in cancer cells can increase sensitivity to chemotherapy while cells with normal checkpoints may take refuge in G1, thus increasing the therapeutic index. ISIS 148715, an inhibitor of Jagged 2, was tested for effects on the cell cycle in normal HMEC cells and cancer cells, both with and without p53. 72 hours after treatment with antisense inhibitor, cells were stained with propidium iodide to generate a cell cycle profile using a flow cytometer. The cell cycle profile was analyzed with the ModFit program (Verity Software House, Inc., Topsham ME). Neither lipofectin alone nor a panel of negative antisense controls perturbed the cell cycle. However, it was found that ISIS 148715 induced apoptosis in all three cell lines, as measured by an increase in the percentage of sub-G1 cells. In T47D cells, the percent hypodiploid cells (indicative of apoptosis) was shown to increase from approximately 4.5% for lipofectin control-

treated cells to approximately 16% for ISIS 148715-treated cells. In MCF7 cells, the percent hypodiploid cells increased from approximately 3% (lipofectin only) to approximately 12.5% (ISIS 148715). In normal HMEC cells
5 the percent diploid cells increased from approximately 2% (lipofectin control) to approximately 8% for cells treated with ISIS 148715. This increase in apoptosis was dose-dependent. In MCF7 cells this increase went from approximately 4% at 200 nM oligonucleotide to 8% at 300 nM
10 oligonucleotide.

What is claimed is:

1. A method for inducing apoptosis in a cell or
5 animal comprising administering to a cell or animal a
Jagged 2 inhibitor in an amount effective to reduce Jagged
2 levels or activity, wherein apoptosis is reduced.

2. The method of claim 1 wherein the Jagged 2
inhibitor comprises a small molecule compound, an
10 inhibitory antibody, a peptide, a peptide fragment, or a
nucleic acid.

3. The method of claim 2 wherein the nucleic acid
comprises an antisense oligonucleotide, an antisense
compound which binds by Watson-Crick base pairing with the
15 Jagged 2 RNA target, a catalytic oligonucleotide or an
inhibitory RNA.

4. The method of claim 2 wherein the peptide or
peptide fragment comprises a Jagged 2 dominant negative
peptide or peptide fragment.

20 5. A method for treating a subject having a
disease or condition associated with insufficient
apoptosis comprising administering to a subject having or
suspected of having a disease or condition associated with
insufficient apoptosis a Jagged 2 inhibitor in an amount
25 effective to reduce Jagged 2 levels or activity.

6. The method of claim 5 wherein the condition
associated with insufficient apoptosis is a
hyperproliferative condition.

7. The method of claim 5 wherein the Jagged 2
30 inhibitor comprises a small molecule compound, an
inhibitory antibody, a peptide, a peptide fragment, or a
nucleic acid.

8. The method of claim 7 wherein the nucleic acid
comprises an antisense oligonucleotide, an antisense
35 compound which binds by Watson-Crick base pairing with the

Jagged 2 RNA target, a catalytic oligonucleotide or an inhibitory RNA.

9. The method of claim 7 wherein the peptide or peptide fragment comprises a Jagged 2 dominant negative peptide or peptide fragment.

10. The method of claim 5 wherein the Jagged 2 inhibitor is administered therapeutically to a subject who has or is suspected of having a condition associated with insufficient apoptosis.

11. The method of claim 5 wherein the Jagged 2 inhibitor is administered prophylactically to a subject who is or is suspected of being at risk for a condition associated with insufficient apoptosis.

12. A pharmaceutical composition comprising a Jagged 2 inhibitor and another active ingredient for inducing apoptosis.

13. A kit comprising a Jagged 2 inhibitor and instructions for using the Jagged 2 inhibitor in the induction of apoptosis.

14. The kit of claim 13 further comprising a second active ingredient for inducing apoptosis.

15. A kit comprising a Jagged 2 inhibitor and instructions for using the Jagged 2 inhibitor in the treatment of a condition associated with insufficient apoptosis.

16. The kit of claim 15 further comprising a second active ingredient for inducing apoptosis.

17. Use of a Jagged 2 inhibitor in the manufacture of a medicament for the treatment of a subject having a disease or condition associated with insufficient apoptosis.

18. The use of claim 17 wherein the condition associated with insufficient apoptosis is a hyperproliferative condition.

19. The use of claim 17 wherein the Jagged 2

100

inhibitor comprises a small molecule compound, an inhibitory antibody, a peptide, a peptide fragment, or a nucleic acid.

20. The use of claim 19 wherein the nucleic acid
5 comprises an antisense oligonucleotide, an antisense compound which binds by Watson-Crick base pairing with the Jagged 2 RNA target, a catalytic oligonucleotide or an inhibitory RNA.

21. The use of claim 19 wherein the peptide or
10 peptide fragment comprises a Jagged 2 dominant negative peptide or peptide fragment.

SEQUENCE LISTING

<110> Isis Pharmaceuticals, Inc.

Erich Koller
Peter J. Shepard

<120> JAGGED 2 INHIBITORS FOR INDUCING APOPTOSIS

<130> ISPH-0733

<150> 10/096,399

<151> 2002-03-12

<160> 91

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1

tccgtcatcg ctcctcaggg

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2

atgcattctg cccccaagga

20

<210> 3

<211> 4749

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (52)...(3768)

<400> 3

ggagcgggcg cgcggcggcg gcggggccgc ggcgggcggg tcgcgggggc a atg cgg
Met Arg
1

57

gcg cag ggc cgg ggg gcc ttc ccc ccg gcg ctg ctg ctg ctg ctg gcg
Ala Gln Gly Arg Gly Ala Phe Pro Pro Ala Leu Leu Leu Leu Leu Ala

105

5

10

15

ctc tgg gtg cag gcg gcg cgg ccc atg ggc tat ttc gag ctg cag ctg Leu Trp Val Gln Ala Ala Arg Pro Met Gly Tyr Phe Glu Leu Gln Leu 20 25 30	153
agc gcg ctg cgg aac gtg aac ggg gag ctg ctg agc ggc gcc tgc tgt Ser Ala Leu Arg Asn Val Asn Gly Glu Leu Leu Ser Gly Ala Cys Cys 35 40 45 50	201
gac ggc gac ggc cgg aca acg cgc gcg ggg ggc tgc ggc cac gac gag Asp Gly Asp Gly Arg Thr Thr Arg Ala Gly Gly Cys Gly His Asp Glu 55 60 65	249
tgc gac acg tac gtg cgc gtg tgc ctt aag gag tac cag gcc aag gtg Cys Asp Thr Tyr Val Arg Val Cys Leu Lys Glu Tyr Gln Ala Lys Val 70 75 80	297
acg ccc acg ggg ccc tgc agc tac ggc cac ggc gcc acg ccc gtg ctg Thr Pro Thr Gly Pro Cys Ser Tyr Gly His Gly Ala Thr Pro Val Leu 85 90 95	345
ggc ggc aac tcc ttc tac ctg ccg ccg gcg ggc gct gcg ggg gac cga Gly Gly Asn Ser Phe Tyr Leu Pro Pro Ala Gly Ala Ala Gly Asp Arg 100 105 110	393
gcg cgc gcg cgg ccc cgg gcc ggc ggc gac cag gac ccg ggc ttc gtc Ala Arg Ala Arg Pro Arg Ala Gly Gly Asp Gln Asp Pro Gly Phe Val 115 120 125 130	441
gtc atc ccc ttc cag ttc gcc tgg ccg cgc tcc ttt acc ctc atc gtg Val Ile Pro Phe Gln Phe Ala Trp Pro Arg Ser Phe Thr Leu Ile Val 135 140 145	489
gag gcc tgg gac tgg gac aac gat acc acc ccg aat gag gag ctg ctg Glu Ala Trp Asp Trp Asp Asn Asp Thr Thr Pro Asn Glu Glu Leu Leu 150 155 160	537
atc gag cga gtg tgc cat gcc ggc atg atc aac ccg gag gac cgc tgg Ile Glu Arg Val Ser His Ala Gly Met Ile Asn Pro Glu Asp Arg Trp 165 170 175	585
aag agc ctg cac ttc agc ggc cac gtg gcg cac ctg gag ctg cag atc Lys Ser Leu His Phe Ser Gly His Val Ala His Leu Glu Leu Gln Ile 180 185 190	633
cgc gtg cgc tgc gac gag aac tac tac agc gcc act tgc aac aag ttc Arg Val Arg Cys Asp Glu Asn Tyr Tyr Ser Ala Thr Cys Asn Lys Phe 195 200 205 210	681
tgc cgg ccc cgc aac gac ttt ttc ggc cac tac acc tgc gac cag tac Cys Arg Pro Arg Asn Asp Phe Phe Gly His Tyr Thr Cys Asp Gln Tyr 215 220 225	729
ggc aac aag gcc tgc atg gac ggc tgg atg ggc aag gag tgc aag gaa Gly Asn Lys Ala Cys Met Asp Gly Trp Met Gly Lys Glu Cys Lys Glu 230 235 240	777
gct gtg tgt aaa caa ggg tgt aat ttg ctc cac ggg gga tgc acc gtg Ala Val Cys Lys Gln Gly Cys Asn Leu Leu His Gly Gly Cys Thr Val	825

245	250	255	
cct ggg gag tgc agg tgc agc tac ggc tgg caa ggg agg ttc tgc gat Pro Gly Glu Cys Arg Cys Ser Tyr Gly Trp Gln Gly Arg Phe Cys Asp 260 265 270			873
gag tgt gtc ccc tac ccc ggc tgc gtg cat ggc agt tgt gtg gag ccc Glu Cys Val Pro Tyr Pro Gly Cys Val His Gly Ser Cys Val Glu Pro 275 280 285 290			921
tgg cag tgc aac tgt gag acc aac tgg ggc ggc ctg ctc tgt gac aaa Trp Gln Cys Asn Cys Glu Thr Asn Trp Gly Gly Leu Leu Cys Asp Lys 295 300 305			969
gac ctg aac tac tgt ggc agc cac cac ccc tgc acc aac gga ggc acg Asp Leu Asn Tyr Cys Gly Ser His His Pro Cys Thr Asn Gly Gly Thr 310 315 320			1017
tgc atc aac gcc gag cct gac cag tac cgc tgc acc tgc cct gac ggc Cys Ile Asn Ala Glu Pro Asp Gln Tyr Arg Cys Thr Cys Pro Asp Gly 325 330 335			1065
tac tcg ggc agg aac tgt gag aag gct gag cac gcc tgc acc tcc aac Tyr Ser Gly Arg Asn Cys Glu Lys Ala Glu His Ala Cys Thr Ser Asn 340 345 350			1113
ccg tgt gcc aac ggg ggc tct tgc cat gag gtg ccg tcc ggc ttc gaa Pro Cys Ala Asn Gly Gly Ser Cys His Glu Val Pro Ser Gly Phe Glu 355 360 365 370			1161
tgc cac tgc cca tcg ggc tgg agc ggg ccc acc tgt gcc ctt gac atc Cys His Cys Pro Ser Gly Trp Ser Gly Pro Thr Cys Ala Leu Asp Ile 375 380 385			1209
gat gag tgt gct tcg aac ccg tgt gcg gcc ggt ggc acc tgt gtg gac Asp Glu Cys Ala Ser Asn Pro Cys Ala Ala Gly Gly Thr Cys Val Asp 390 395 400			1257
cag gtg gac ggc ttt gag tgc atc tgc ccc gag cag tgg gtg ggg gcc Gln Val Asp Gly Phe Glu Cys Ile Cys Pro Glu Gln Trp Val Gly Ala 405 410 415			1305
acc tgc cag ctg gac gtc aac gac tgt gaa ggg aag cca tgc ctt aac Thr Cys Gln Leu Asp Val Asn Asp Cys Glu Gly Lys Pro Cys Leu Asn 420 425 430			1353
gct ttt tct tgc aaa aac ctg att ggc ggc tat tac tgt gat tgc atc Ala Phe Ser Cys Lys Asn Leu Ile Gly Gly Tyr Tyr Cys Asp Cys Ile 435 440 445 450			1401
ccg ggc tgg aag ggc atc aac tgc cat atc aac gtc aac gac tgt cgc Pro Gly Trp Lys Gly Ile Asn Cys His Ile Asn Val Asn Asp Cys Arg 455 460 465			1449
ggg cag tgt cag cat ggg ggc acc tgc aag gac ctg gtg aac ggg tac Gly Gln Cys Gln His Gly Gly Thr Cys Lys Asp Leu Val Asn Gly Tyr 470 475 480			1497
cag tgt gtg tgc cca cgg ggc ttc gga ggc cgg cat tgc gag ctg gaa			1545

Gln	Cys	Val	Cys	Pro	Arg	Gly	Phe	Gly	Gly	Arg	His	Cys	Glu	Leu	Glu	
485						490						495				
cga	gac	aag	tgt	gcc	agc	agc	ccc	tgc	cac	agc	ggc	ggc	ctc	tgc	gag	1593
Arg	Asp	Lys	Cys	Ala	Ser	Ser	Pro	Cys	His	Ser	Gly	Gly	Leu	Cys	Glu	
500						505						510				
gac	ctg	gcc	gac	ggc	ttc	cac	tgc	cac	tgc	ccc	cag	ggc	ttc	tcc	ggg	1641
Asp	Leu	Ala	Asp	Gly	Phe	His	Cys	His	Cys	Pro	Gln	Gly	Phe	Ser	Gly	
515				520						525				530		
cct	ctc	tgt	gag	gtg	gat	gtc	gac	ctt	tgt	gag	cca	agc	ccc	tgc	cgg	1689
Pro	Leu	Cys	Glu	Val	Asp	Val	Asp	Leu	Cys	Glu	Pro	Ser	Pro	Cys	Arg	
				535				540						545		
aac	ggc	gct	cgc	tgc	tat	aac	ctg	gag	ggc	gac	tat	tac	tgc	gcc	tgc	1737
Asn	Gly	Ala	Arg	Cys	Tyr	Asn	Leu	Glu	Gly	Asp	Tyr	Tyr	Cys	Ala	Cys	
		550				555						560				
cct	gat	gac	ttt	ggc	ggc	aag	aac	tgc	tcc	gtg	ccc	cgc	gag	ccg	tgc	1785
Pro	Asp	Asp	Phe	Gly	Gly	Lys	Asn	Cys	Ser	Val	Pro	Arg	Glu	Pro	Cys	
		565				570						575				
cct	ggc	ggg	gcc	tgc	aga	gtg	atc	gat	ggc	tgc	ggg	tca	gac	gcg	ggg	1833
Pro	Gly	Gly	Ala	Cys	Arg	Val	Ile	Asp	Gly	Cys	Gly	Ser	Asp	Ala	Gly	
580						585				590						
cct	ggg	atg	cct	ggc	aca	gca	gcc	tcc	ggc	gtg	tgt	ggc	ccc	cat	gga	1881
Pro	Gly	Met	Pro	Gly	Thr	Ala	Ala	Ser	Gly	Val	Cys	Gly	Pro	His	Gly	
595				600				605						610		
cgc	tgc	gtc	agc	cag	cca	ggg	ggc	aac	ttt	tcc	tgc	atc	tgt	gac	agt	1929
Arg	Cys	Val	Ser	Gln	Pro	Gly	Gly	Asn	Phe	Ser	Cys	Ile	Cys	Asp	Ser	
				615				620						625		
ggc	ttt	act	ggc	acc	tac	tgc	cat	gag	aac	att	gac	gac	tgc	ctg	ggc	1977
Gly	Phe	Thr	Gly	Thr	Tyr	Cys	His	Glu	Asn	Ile	Asp	Asp	Cys	Leu	Gly	
		630				635						640				
cag	ccc	tgc	cgc	aat	ggg	ggc	aca	tgc	atc	gat	gag	gtg	gac	gcc	ttc	2025
Gln	Pro	Cys	Arg	Asn	Gly	Gly	Thr	Cys	Ile	Asp	Glu	Val	Asp	Ala	Phe	
		645				650						655				
cgc	tgc	ttc	tgc	ccc	agc	ggc	tgg	gag	ggc	gag	ctc	tgc	gac	acc	aat	2073
Arg	Cys	Phe	Cys	Pro	Ser	Gly	Trp	Glu	Gly	Glu	Leu	Cys	Asp	Thr	Asn	
660						665				670						
ccc	aac	gac	tgc	ctt	ccc	gat	ccc	tgc	cac	agc	cgc	ggc	cgc	tgc	tac	2121
Pro	Asn	Asp	Cys	Leu	Pro	Asp	Pro	Cys	His	Ser	Arg	Gly	Arg	Cys	Tyr	
675				680						685				690		
gac	ctg	gtc	aat	gac	ttc	tac	tgt	gcg	tgc	gac	gac	ggc	tgg	aag	ggc	2169
Asp	Leu	Val	Asn	Asp	Phe	Tyr	Cys	Ala	Cys	Asp	Asp	Gly	Trp	Lys	Gly	
				695				700				705				
aag	acc	tgc	cac	tca	cgc	gag	ttc	cag	tgc	gat	gcc	tac	acc	tgc	agc	2217
Lys	Thr	Cys	His	Ser	Arg	Glu	Phe	Gln	Cys	Asp	Ala	Tyr	Thr	Cys	Ser	
		710				715				720						

aac ggt ggc acc tgc tac gac agc ggc gac acc ttc cgc tgc gcc tgc	2265
Asn Gly Gly Thr Cys Tyr Asp Ser Gly Asp Thr Phe Arg Cys Ala Cys	
725 730 735	
ccc ccc ggc tgg aag ggc agc acc tgc gcc gtc gcc aag aac agc agc	2313
Pro Pro Gly Trp Lys Gly Ser Thr Cys Ala Val Ala Lys Asn Ser Ser	
740 745 750	
tgc ctg ccc aac ccc tgt gtg aat ggt ggc acc tgc gtg ggc agc ggg	2361
Cys Leu Pro Asn Pro Cys Val Asn Gly Gly Thr Cys Val Gly Ser Gly	
755 760 765 770	
gcc tcc ttc tcc tgc atc tgc cgg gac ggc tgg gag ggt cgt act tgc	2409
Ala Ser Phe Ser Cys Ile Cys Arg Asp Gly Trp Glu Gly Arg Thr Cys	
775 780 785	
act cac aat acc aac gac tgc aac cct ctg cct tgc tac aat ggt ggc	2457
Thr His Asn Thr Asn Asp Cys Asn Pro Leu Pro Cys Tyr Asn Gly Gly	
790 795 800	
atc tgt gtt gac ggc gtc aac tgg ttc cgc tgc gag tgt gca cct ggc	2505
Ile Cys Val Asp Gly Val Asn Trp Phe Arg Cys Glu Cys Ala Pro Gly	
805 810 815	
ttc gcg ggg cct gac tgc cgc atc aac atc gac gag tgc cag tcc tcg	2553
Phe Ala Gly Pro Asp Cys Arg Ile Asn Ile Asp Glu Cys Gln Ser Ser	
820 825 830	
ccc tgt gcc tac ggg gcc acg tgt gtg gat gag atc aac ggg tat cgc	2601
Pro Cys Ala Tyr Gly Ala Thr Cys Val Asp Glu Ile Asn Gly Tyr Arg	
835 840 845 850	
tgt agc tgc cca ccc ggc cga gcc ggc ccc cgg tgc cag gaa gtg atc	2649
Cys Ser Cys Pro Pro Gly Arg Ala Gly Pro Arg Cys Gln Glu Val Ile	
855 860 865	
ggg ttc ggg aga tcc tgc tgg tcc cgg ggc act ccg ttc cca cac gga	2697
Gly Phe Gly Arg Ser Cys Trp Ser Arg Gly Thr Pro Phe Pro His Gly	
870 875 880	
agc tcc tgg gtg gaa gac tgc aac agc tgc cgc tgc ctg gat ggc cgc	2745
Ser Ser Trp Val Glu Asp Cys Asn Ser Cys Arg Cys Leu Asp Gly Arg	
885 890 895	
cgt gac tgc agc aag gtg tgg tgc gga tgg aag cct tgt ctg ctg gcc	2793
Arg Asp Cys Ser Lys Val Trp Cys Gly Trp Lys Pro Cys Leu Leu Ala	
900 905 910	
ggc cag ccc gag gcc ctg agc gcc cag tgc cca ctg ggg caa agg tgc	2841
Gly Gln Pro Glu Ala Leu Ser Ala Gln Cys Pro Leu Gly Gln Arg Cys	
915 920 925 930	
ctg gag aag gcc cca ggc cag tgt ctg cga cca ccc tgt gag gcc tgg	2889
Leu Glu Lys Ala Pro Gly Gln Cys Leu Arg Pro Pro Cys Glu Ala Trp	
935 940 945	
ggg gag tgc ggc gca gaa gag cca ccg agc acc ccc tgc ctg cca cgc	2937
Gly Glu Cys Gly Ala Glu Glu Pro Pro Ser Thr Pro Cys Leu Pro Arg	
950 955 960	

tcc ggc cac ctg gac aat aac tgt gcc cgc ctc acc ttg cat ttc aac	2985
Ser Gly His Leu Asp Asn Asn Cys Ala Arg Leu Thr Leu His Phe Asn	
965 970 975	
cgt gac cac gtg ccc cag ggc acc acg gtg ggc gcc att tgc tcc ggg	3033
Arg Asp His Val Pro Gln Gly Thr Thr Val Gly Ala Ile Cys Ser Gly	
980 985 990	
atc cgc tcc ctg cca gcc aca agg gct gtg gca cgg gac cgc ctg ctg	3081
Ile Arg Ser Leu Pro Ala Thr Arg Ala Val Ala Arg Asp Arg Leu Leu	
995 1000 1005 1010	
gtg ttg ctt tgc gac cgg gcg tcc tcg ggg gcc agt gcc gtg gag gtg	3129
Val Leu Leu Cys Asp Arg Ala Ser Ser Gly Ala Ser Ala Val Glu Val	
1015 1020 1025	
gcc gtg tcc ttc agc cct gcc agg gac ctg cct gac agc agc ctg atc	3177
Ala Val Ser Phe Ser Pro Ala Arg Asp Leu Pro Asp Ser Ser Leu Ile	
1030 1035 1040	
cag ggc gcg gcc cac gcc atc gtg gcc gcc atc acc cag cgg ggg aac	3225
Gln Gly Ala Ala His Ala Ile Val Ala Ala Ile Thr Gln Arg Gly Asn	
1045 1050 1055	
agc tca ctg ctc ctg gct gtc acc gag gtc aag gtg gag acg gtt gtt	3273
Ser Ser Leu Leu Leu Ala Val Thr Glu Val Lys Val Glu Thr Val Val	
1060 1065 1070	
acg ggc ggc tct tcc aca ggt ctg ctg gtg cct gtg ctg tgt ggt gcc	3321
Thr Gly Gly Ser Ser Thr Gly Leu Leu Val Pro Val Leu Cys Gly Ala	
1075 1080 1085 1090	
ttc agc gtg ctg tgg ctg gcg tgc gtg gtc ctg tgc gtg tgg tgg aca	3369
Phe Ser Val Leu Trp Leu Ala Cys Val Val Leu Cys Val Trp Trp Thr	
1095 1100 1105	
cgc aag cgc agg aaa gag cgg gag agg agc cgg ctg ccg cgg gag gag	3417
Arg Lys Arg Arg Lys Glu Arg Glu Arg Ser Arg Leu Pro Arg Glu Glu	
1110 1115 1120	
agc gcc aac aac cag tgg gcc ccg ctc aac ccc atc cgc aac ccc atc	3465
Ser Ala Asn Asn Gln Trp Ala Pro Leu Asn Pro Ile Arg Asn Pro Ile	
1125 1130 1135	
gag cgg ccg ggg ggc cac aag gac gtg ctc tac cag tgc aag aac ttc	3513
Glu Arg Pro Gly Gly His Lys Asp Val Leu Tyr Gln Cys Lys Asn Phe	
1140 1145 1150	
acg ccg ccg ccg cgc agg gcg gac gag gcg ctg ccc ggg ccg gcc ggc	3561
Thr Pro Pro Pro Arg Arg Ala Asp Glu Ala Leu Pro Gly Pro Ala Gly	
1155 1160 1165 1170	
cac gcg gcc gtc agg gag gat gag gag gac gag gat ctg ggc cgc ggt	3609
His Ala Ala Val Arg Glu Asp Glu Glu Asp Glu Asp Leu Gly Arg Gly	
1175 1180 1185	
gag gag gac tcc ctg gag gcg gag aag ttc ctc tca cac aaa ttc acc	3657
Glu Glu Asp Ser Leu Glu Ala Glu Lys Phe Leu Ser His Lys Phe Thr	

7

1190	1195	1200	
aaa gat cct ggc cgc tcg ccg ggg agg ccg gcc cac tgg gcc tca ggc			3705
Lys Asp Pro Gly Arg Ser Pro Gly Arg Pro Ala His Trp Ala Ser Gly			
1205	1210	1215	
ccc aaa gtg gac aac cgc gcg gtc agg agc atc aat gag gcc cgc tac			3753
Pro Lys Val Asp Asn Arg Ala Val Arg Ser Ile Asn Glu Ala Arg Tyr			
1220	1225	1230	
gcc gcc aag gag tag gggcggctgc agctgggccc ggacccaggg ccctcggtgg			3808
Ala Gly Lys Glu			
1235			
gagccatgcc gtctgccgga ccgaggccg aggcattgtgc atagtttctt tatttttgtgt			3868
aaaaaaacca ccaaaaacaa aaaccaaagt tttattttct acgtttcttt aaccttgtat			3928
aaattattca gtaactgtca ggctgaaaac aatggagtat tctcggatag ttgctatattt			3988
tgtaaagttt ccgtgcgtgg cactcgctgt atgaaaggag agagcaaagg gtgtctgcgt			4048
cgtcaccaaa tcgtagcgtt tgttaccaga ggttgtgcac tgtttacaga atcttccttt			4108
tattcctcac tcgggtttct ctgtggctcc aggccaaagt gccggtgaga cccatggctg			4168
tgttggtgtg gcccatggct gttggtggga ccggtggctg atggtgtggc ctgtggctgt			4228
cgggtgggact cgtggctgtc aatgggacct gtggctgtcg gtgggacctt cgggtggctgg			4288
tgggacctg gttattgatg tggccctggc tgccggcacg gcccggtggct gttgacgcac			4348
ctgtggttgt tagtggggcc tgaggtcatc ggcgtgccca aggccggcag gtcaacctcg			4408
cgtttgctgg ccagtccacc ctgcctgccg tctgtgcttc ctctgccca gaacgcccgc			4468
tccagcgatc tctccactgt gctttcagaa gtgcccttcc tgctgcgcag ttctcccatc			4528
ctgggacggc ggcagtattg aagctcgtga caagtgcctt cacacagacc cctcgcaact			4588
gtccacgcgt gccgtggcac caggcgtgc ccacctgccg gcccgggccg cccctcctcg			4648
tgaaagtgca tttttgtaaa tgtgtacata ttaaaggaag cactctgtat atttgattga			4708
ataatgccac caaaaaaaaaa aaaaaaaaaa aattcctgcc c			4749

<210> 4

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 4

cccagggttt ctccgg

16

<210> 5
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 5
aatagtcacc ctccaggtta tagcag

26

<210> 6
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Probe

<400> 6
tggatgtcga cctttgtgag ccaagc

26

<210> 7
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 7
gaaggtgaag gtccggagtc

19

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 8
gaagatggtg atgggatttc

20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Probe

<400> 9
caagcttccc gttctcagcc

20

```
<220>
<221> CDS
<222> (405)...(4121)
```

<400> 10	
ctcatgcata tgcaggtgcg cgggtgacga atgggcgagc gagctgtcag tctcgttccg	60
aacttgttgg ctgcggtgcc gggagcgcg ggcgcagag cccgaggccg ggaccgcgtg	120
ccttcaccgc cgccgccgtc gccgccgggt gggagccggg ccgggcagcc ggagcgcggc	180
cgccagcgag ccggagctgc cgccgccct gcacgccgc cgccaggcc cgcgcgccg	240
acgctgcgt ctgacccgcc cgcgcgcgc ccgccgcgc ctctgccgt gccgtgcct	300
ctgcggggcg tcggagggcg ggcgggcgt gggaggccg cgcggcggt gggagccggg	360
cgcggggcgc ggcggcggg ccgggcgggc gggtcgcggg ggca atg cgg gcg cag	416
	Met Arg Ala Gln
	1
ggc cgg ggg cgc ctt ccc cgg cgg ctg ctg ctg ctg ctg gcg ctc tgg	464
Gly Arg Gly Arg Leu Pro Arg Arg Leu Leu Leu Leu Leu Ala Leu Trp	
5 10 15 20	
gtg cag gcg gcg cgg ccc atg ggc tat ttc gag ctg cag ctg agc gcg	512
Val Gln Ala Ala Arg Pro Met Gly Tyr Phe Glu Leu Gln Leu Ser Ala	
25 30 35	
ctg cgg aac gtg aac ggg gag ctg ctg agc ggc gcc tgc tgt gac ggc	560
Leu Arg Asn Val Asn Gly Glu Leu Leu Ser Gly Ala Cys Asp Gly	
40 45 50	
gac ggc cgg aca acg cgc gcg ggg ggc tgc ggc cac gac gag tgc gac	608
Asp Gly Arg Thr Thr Arg Ala Gly Gly Cys Gly His Asp Glu Cys Asp	
55 60 65	
acg tac gtg cgc gtg tgc ctt aag gag tac cag gcc aag gtg acg ccc	656
Thr Tyr Val Arg Val Cys Leu Lys Glu Tyr Gln Ala Lys Val Thr Pro	
70 75 80	
acg ggg ccc tgc agc tac ggc cac ggc gcc acg ccc gtg ctg ggc ggc	704
Thr Gly Pro Cys Ser Tyr Gly His Gly Ala Thr Pro Val Leu Gly Gly	
85 90 95 100	
aac tcc ttc tac ctg ccg ccg gcg ggc gct gcg ggg gac cga gcg cgg	752
Asn Ser Phe Tyr Leu Pro Pro Ala Gly Ala Ala Gly Asp Arg Ala Arg	
105 110 115	
gcg cgg gcc cgg gcc ggc ggc gac cag gac ccg ggc ctc gtc gtc atc	800
Ala Arg Ala Arg Ala Gly Gly Asp Gln Asp Pro Gly Leu Val Val Ile	
120 125 130	

ccc ttc cag ttc gcc tgg ccg cgc tcc ttt acc ctc atc gtg gag gcc	848
Pro Phe Gln Phe Ala Trp Pro Arg Ser Phe Thr Leu Ile Val Glu Ala	
135 140 145	
tgg gac tgg gac aac gat acc acc ccg aat gag gag ctg ctg atc gag	896
Trp Asp Trp Asp Asn Asp Thr Thr Pro Asn Glu Glu Leu Leu Ile Glu	
150 155 160	
cga gtg tgc cat gcc ggc atg atc aac ccg gag gag cgc tgg aag agc	944
Arg Val Ser His Ala Gly Met Ile Asn Pro Glu Asp Arg Trp Lys Ser	
165 170 175 180	
ctg cac ttc agc ggc cac gtg gcg cac ctg gag ctg cag atc cgc gtg	992
Leu His Phe Ser Gly His Val Ala His Leu Glu Leu Gln Ile Arg Val	
185 190 195	
cgc tgc gac gag aac tac tac agc gcc act tgc aac aag ttc tgc ccg	1040
Arg Cys Asp Glu Asn Tyr Tyr Ser Ala Thr Cys Asn Lys Phe Cys Arg	
200 205 210	
ccc cgc aac gac ttt ttc ggc cac tac acc tgc gac cag tac ggc aac	1088
Pro Arg Asn Asp Phe Phe Gly His Tyr Thr Cys Asp Gln Tyr Gly Asn	
215 220 225	
aag gcc tgc atg gac ggc tgg atg ggc aag gag tgc aag gaa gct gtg	1136
Lys Ala Cys Met Asp Gly Trp Met Gly Lys Glu Cys Lys Glu Ala Val	
230 235 240	
tgt aaa caa ggg tgt aat ttg ctc cac ggg gga tgc acc gtg cct ggg	1184
Cys Lys Gln Gly Cys Asn Leu Leu His Gly Gly Cys Thr Val Pro Gly	
245 250 255 260	
gag tgc agg tgc agc tac ggc tgg caa ggg agg ttc tgc gat gag tgt	1232
Glu Cys Arg Cys Ser Tyr Gly Trp Gln Gly Arg Phe Cys Asp Glu Cys	
265 270 275	
gtc ccc tac ccc ggc tgc gtg cat ggc agt tgt gtg gag ccc tgg cag	1280
Val Pro Tyr Pro Gly Cys Val His Gly Ser Cys Val Glu Pro Trp Gln	
280 285 290	
tgc aac tgt gag acc aac tgg ggc ggc ctg ctc tgt gac aaa gac ctg	1328
Cys Asn Cys Glu Thr Asn Trp Gly Gly Leu Leu Cys Asp Lys Asp Leu	
295 300 305	
aac tac tgt ggc agc cac cac ccc tgc acc aac gga ggc acg tgc atc	1376
Asn Tyr Cys Gly Ser His His Pro Cys Thr Asn Gly Gly Thr Cys Ile	
310 315 320	
aac gcc gag cct gac cag tac cgc tgc acc tgc cct gac ggc tac tcg	1424
Asn Ala Glu Pro Asp Gln Tyr Arg Cys Thr Cys Pro Asp Gly Tyr Ser	
325 330 335 340	
ggc agg aac tgt gag aag gct gag cac gcc tgc acc tcc aac ccg tgt	1472
Gly Arg Asn Cys Glu Lys Ala Glu His Ala Cys Thr Ser Asn Pro Cys	
345 350 355	
gcc aac ggg ggc tct tgc cat gag gtg ccg tcc ggc ttc gaa tgc cac	1520
Ala Asn Gly Gly Ser Cys His Glu Val Pro Ser Gly Phe Glu Cys His	
360 365 370	

tgc cca tcg ggc tgg agc ggg ccc acc tgt gcc ctt gac atc gat gag Cys Pro Ser Gly Trp Ser Gly Pro Thr Cys Ala Leu Asp Ile Asp Glu 375 380 385	1568
tgt gct tcg aac ccg tgt gcg gcc ggt ggc acc tgt gtg gac cag gtg Cys Ala Ser Asn Pro Cys Ala Ala Gly Gly Thr Cys Val Asp Gln Val 390 395 400	1616
gac ggc ttt gag tgc atc tgc ccc gag cag tgg gtg ggg gcc acc tgc Asp Gly Phe Glu Cys Ile Cys Pro Glu Gln Trp Val Gly Ala Thr Cys 405 410 415 420	1664
cag ctg gac gcc aat gag tgt gaa ggg aag cca tgc ctt aac gct ttt Gln Leu Asp Ala Asn Glu Cys Glu Gly Lys Pro Cys Leu Asn Ala Phe 425 430 435	1712
tct tgc aaa aac ctg att ggc ggc tat tac tgt gat tgc atc ccg ggc Ser Cys Lys Asn Leu Ile Gly Gly Tyr Tyr Cys Asp Cys Ile Pro Gly 440 445 450	1760
tgg aag ggc atc aac tgc cat atc aac gtc aac gac tgt cgc ggg cag Trp Lys Gly Ile Asn Cys His Ile Asn Val Asn Asp Cys Arg Gly Gln 455 460 465	1808
tgt cag cat ggg ggc acc tgc aag gac ctg gtg aac ggg tac cag tgt Cys Gln His Gly Gly Thr Cys Lys Asp Leu Val Asn Gly Tyr Gln Cys 470 475 480	1856
gtg tgc cca cgg ggc ttc gga ggc cgg cat tgc gag ctg gaa cga gac Val Cys Pro Arg Gly Phe Gly Gly Arg His Cys Glu Leu Glu Arg Asp 485 490 495 500	1904
aag tgt gcc agc agc ccc tgc cac agc ggc ggc ctc tgc gag gac ctg Lys Cys Ala Ser Ser Pro Cys His Ser Gly Gly Leu Cys Glu Asp Leu 505 510 515	1952
gcc gac ggc ttc cac tgc cac tgc ccc cag ggc ttc tcc ggg cct ctc Ala Asp Gly Phe His Cys His Cys Pro Gln Gly Phe Ser Gly Pro Leu 520 525 530	2000
tgt gag gtg gat gtc gac ctt tgt gag cca agc ccc tgc cgg aac ggc Cys Glu Val Asp Val Asp Leu Cys Glu Pro Ser Pro Cys Arg Asn Gly 535 540 545	2048
gct cgc tgc tat aac ctg gag ggt gac tat tac tgc gcc tgc cct gat Ala Arg Cys Tyr Asn Leu Glu Gly Asp Tyr Tyr Cys Ala Cys Pro Asp 550 555 560	2096
gac ttt ggt ggc aag aac tgc tcc gtg ccc cgc gag ccg tgc cct ggc Asp Phe Gly Gly Lys Asn Cys Ser Val Pro Arg Glu Pro Cys Pro Gly 565 570 575 580	2144
ggg gcc tgc aga gtg atc gat ggc tgc ggg tca gac gcg ggg cct ggg Gly Ala Cys Arg Val Ile Asp Gly Cys Gly Ser Asp Ala Gly Pro Gly 585 590 595	2192
atg cct ggc aca gca gcc tcc ggc gtg tgt ggc ccc cat gga cgc tgc Met Pro Gly Thr Ala Ala Ser Gly Val Cys Gly Pro His Gly Arg Cys	2240

600	605	610	
gtc agc cag cca ggg ggc aac ttt tcc tgc atc tgt gac agt ggc ttt Val Ser Gln Pro Gly Gly Asn Phe Ser Cys Ile Cys Asp Ser Gly Phe 615 620 625			2288
act ggc acc tac tgc cat gag aac att gac gac tgc ctg ggc cag ccc Thr Gly Thr Tyr Cys His Glu Asn Ile Asp Asp Cys Leu Gly Gln Pro 630 635 640			2336
tgc cgc aat ggg ggc aca tgc atc gat gag gtg gac gcc ttc cgc tgc Cys Arg Asn Gly Gly Thr Cys Ile Asp Glu Val Asp Ala Phe Arg Cys 645 650 655 660			2384
ttc tgc ccc agc ggc tgg gag ggc gag ctc tgc gac acc aat ccc aac Phe Cys Pro Ser Gly Trp Glu Gly Glu Leu Cys Asp Thr Asn Pro Asn 665 670 675			2432
gac tgc ctt ccc gat ccc tgc cac agc cgc ggc cgc tgc tac gac ctg Asp Cys Leu Pro Asp Pro Cys His Ser Arg Gly Arg Cys Tyr Asp Leu 680 685 690			2480
gtc aat gac ttc tac tgt gcg tgc gac gac ggc tgg aag ggc aag acc Val Asn Asp Phe Tyr Cys Ala Cys Asp Asp Gly Trp Lys Gly Lys Thr 695 700 705			2528
tgc cac tca cgc gag ttc cag tgc gat gcc tac acc tgc agc aac ggt Cys His Ser Arg Glu Phe Gln Cys Asp Ala Tyr Thr Cys Ser Asn Gly 710 715 720			2576
ggc acc tgc tac gac agc ggc gac acc ttc cgc tgc gcc tgc ccc ccc Gly Thr Cys Tyr Asp Ser Gly Asp Thr Phe Arg Cys Ala Cys Pro Pro 725 730 735 740			2624
ggc tgg aag ggc agc acc tgc gcc gtc gcc aag aac agc agc tgc ctg Gly Trp Lys Gly Ser Thr Cys Ala Val Ala Lys Asn Ser Ser Cys Leu 745 750 755			2672
ccc aac ccc tgt gtg aat ggt ggc acc tgc gtg ggc agc ggg gcc tcc Pro Asn Pro Cys Val Asn Gly Gly Thr Cys Val Gly Ser Gly Ala Ser 760 765 770			2720
ttc tcc tgc atc tgc cgg gac ggc tgg gag ggt cgt act tgc act cac Phe Ser Cys Ile Cys Arg Asp Gly Trp Glu Gly Arg Thr Cys Thr His 775 780 785			2768
aat acc aac gac tgc aac cct ctg cct tgc tac aat ggt ggc atc tgt Asn Thr Asn Asp Cys Asn Pro Leu Pro Cys Tyr Asn Gly Gly Ile Cys 790 795 800			2816
gtt gac ggc gtc aac tgg ttc cgc tgc gag tgt gca cct ggc ttc gcg Val Asp Gly Val Asn Trp Phe Arg Cys Glu Cys Ala Pro Gly Phe Ala 805 810 815 820			2864
ggg cct gac tgc cgc atc aac atc gac gag tgc cag tcc tcg ccc tgt Gly Pro Asp Cys Arg Ile Asn Ile Asp Glu Cys Gln Ser Ser Pro Cys 825 830 835			2912
gcc tac ggg gcc acg tgt gtg gat gag atc aac ggg tat cgc tgt agc			2960

Ala Tyr Gly Ala Thr Cys Val Asp Glu Ile Asn Gly Tyr Arg Cys Ser	
840	845 850
tgc cca ccc ggc cga gcc ggc ccc cgg tgc cag gaa gtg atc ggg ttc	3008
Cys Pro Pro Gly Arg Ala Gly Pro Arg Cys Gln Glu Val Ile Gly Phe	
855	860 865
ggg aga tcc tgc tgg tcc cgg ggc act ccg ttc cca cac gga agc tcc	3056
Gly Arg Ser Cys Trp Ser Arg Gly Thr Pro Phe Pro His Gly Ser Ser	
870	875 880
tgg gtg gaa gac tgc aac agc tgc cgc tgc ctg gat ggc cgc cgt gac	3104
Trp Val Glu Asp Cys Asn Ser Cys Arg Cys Leu Asp Gly Arg Arg Asp	
885	890 895 900
tgc agc aag gtg tgg tgc gga tgg aag cct tgt ctg ctg gcc ggc cag	3152
Cys Ser Lys Val Trp Cys Gly Trp Lys Pro Cys Leu Leu Ala Gly Gln	
905	910 915
ccc gag gcc ctg agc gcc cag tgc cca ctg ggg caa agg tgc ctg gag	3200
Pro Glu Ala Leu Ser Ala Gln Cys Pro Leu Gly Gln Arg Cys Leu Glu	
920	925 930
aag gcc cca ggc cag tgt ctg cga cca ccc tgt gag gcc tgg ggg gag	3248
Lys Ala Pro Gly Gln Cys Leu Arg Pro Pro Cys Glu Ala Trp Gly Glu	
935	940 945
tgc ggc gca gaa gag cca ccg agc acc ccc tgc ctg cca cgc tcc ggc	3296
Cys Gly Ala Glu Glu Pro Pro Ser Thr Pro Cys Leu Pro Arg Ser Gly	
950	955 960
cac ctg gac aat aac tgt gcc cgc ctc acc ttg cat ttc aac cgt gac	3344
His Leu Asp Asn Asn Cys Ala Arg Leu Thr Leu His Phe Asn Arg Asp	
965	970 975 980
cac gtg ccc cag ggc acc acg gtg ggc gcc att tgc tcc ggg atc cgc	3392
His Val Pro Gln Gly Thr Thr Val Gly Ala Ile Cys Ser Gly Ile Arg	
985	990 995
tcc ctg cca gcc aca agg gct gtg gca cgg gac cgc ctg ctg gtg ttg	3440
Ser Leu Pro Ala Thr Arg Ala Val Ala Arg Asp Arg Leu Leu Val Leu	
1000	1005 1010
ctt tgc gac cgg gcg tcc tcg ggg gcc agt gcc gtg gag gtg gcc gtg	3488
Leu Cys Asp Arg Ala Ser Ser Gly Ala Ser Ala Val Glu Val Ala Val	
1015	1020 1025
tcc ttc agc cct gcc agg gac ctg cct gac agc agc ctg atc cag ggc	3536
Ser Phe Ser Pro Ala Arg Asp Leu Pro Asp Ser Ser Leu Ile Gln Gly	
1030	1035 1040
gcg gcc cac gcc atc gtg gcc gcc atc acc cag cgg ggg aac agc tca	3584
Ala Ala His Ala Ile Val Ala Ala Ile Thr Gln Arg Gly Asn Ser Ser	
1045	1050 1055 1060
ctg ctc ctg gct gtc acc gag gtc aag gtg gag acg gtt gtt acg ggc	3632
Leu Leu Leu Ala Val Thr Glu Val Lys Val Glu Thr Val Val Thr Gly	
1065	1070 1075

14

ggc tct tcc aca ggt ctg ctg gtg cct gtg ctg tgt ggt gcc ttc agc Gly Ser Ser Thr Gly Leu Leu Val Pro Val Leu Cys Gly Ala Phe Ser 1080 1085 1090	3680
gtg ctg tgg ctg gcg tgc gtg gtc ctg tgc gtg tgg tgg aca cgc aag Val Leu Trp Leu Ala Cys Val Val Leu Cys Val Trp Trp Thr Arg Lys 1095 1100 1105	3728
cgc agg aaa gag cgg gag agg agc cgg ctg ccg cgg gag gag agc gcc Arg Arg Lys Glu Arg Glu Arg Ser Arg Leu Pro Arg Glu Glu Ser Ala 1110 1115 1120	3776
aac aac cag tgg gcc ccg ctc aac ccc atc cgc aac ccc atc gag cgg Asn Asn Gln Trp Ala Pro Leu Asn Pro Ile Arg Asn Pro Ile Glu Arg 1125 1130 1135 1140	3824
ccg ggg ggc cac aag gac gtg ctc tac cag tgc aag aac ttc acg ccg Pro Gly Gly His Lys Asp Val Leu Tyr Gln Cys Lys Asn Phe Thr Pro 1145 1150 1155	3872
ccg ccg cgc agg gcg gac gag gcg ctg ccc ggg ccg gcc ggc cac gcg Pro Pro Arg Arg Ala Asp Glu Ala Leu Pro Gly Pro Ala Gly His Ala 1160 1165 1170	3920
gcc gtc agg gag gat gag gag gac gag gat ctg ggc cgc ggt gag gag Ala Val Arg Glu Asp Glu Glu Asp Glu Asp Leu Gly Arg Gly Glu Glu 1175 1180 1185	3968
gac tcc ctg gag gcg gag aag ttc ctc tca cac aaa ttc acc aaa gat Asp Ser Leu Glu Ala Glu Lys Phe Leu Ser His Lys Phe Thr Lys Asp 1190 1195 1200	4016
cct ggc cgc tcg ccg ggg agg ccg gcc cac tgg gcc tca ggc ccc aaa Pro Gly Arg Ser Pro Gly Arg Pro Ala His Trp Ala Ser Gly Pro Lys 1205 1210 1215 1220	4064
gtg gac aac cgc gcg gtc agg agc atc aat gag gcc cgc tac gcc ggc Val Asp Asn Arg Ala Val Arg Ser Ile Asn Glu Ala Arg Tyr Ala Gly 1225 1230 1235	4112
aag gag tag gggcggtgc cagctgggcc gggaccagg gccctcggtg ggagccatgc Lys Glu	4171
cgctctgccgg acccgagggc cgaggccatg tgcatagttt ctttattttg tgtaaaaaaa	4231
ccaccaaaaa caaaaaccaa atgtttatct tctacgtttc tttaaccttg tataaattat	4291
tcagtaactg tcaggctgaa aacaatggag tattctcgga tagttgctat ttttgtaaag	4351
tttccgtgcg tggcactcgc tgtatgaaag gagagagcaa aggggtgtctg cgtcgtcacc	4411
aaatcgtagc gtttggtacc agaggttgtg cactgtttac agaattcttc ttttattcct	4471
cactcggtgt tctctgtggc tccaggccaa agtgccggtg agacccatgg ctgtgttggt	4531
gtggcccatg gctgttggtg ggaccogtgg ctgatgggtg ggcctgtggc tgtcgggtggg	4591
actcgtggct gtcaatggga cctgtggctg tcgggtgggac ctacgggtggt cgggtgggacc	4651

ctgggttattg atgtggccct gggtgccggc acggcccggtg gctgttgacg cacctgtggg 4711
 tgttagtgagg gctgaggtc atcggcgtgg cccaaggccg gcaggtcaac ctgcgccttg 4771
 ctggccagtc caccctgcct gcggtctgtg cttcctcctg ccagaacgc ccgtccagc 4831
 gatctctcca ctgtgctttc agaagtgcc ttcctgctgc gaagttctcc catcctggga 4891
 cggcggcagt attgaagctc gtgacaagtg ccttcacaca gaaccctcgg aactgtccac 4951
 gcgttccgtg ggaacaaggg gtt 4974

<210> 11
 <211> 28000
 <212> DNA
 <213> Homo sapiens

<400> 11
 aggtgacccc tagctctgga aaggaccgtg ctcaactggag gagaggaagg tgccattggg 60
 tttgaccctg tggaggagct gcgaggtcac ccaggagagag ggcaaggagg tgaccgcaga 120
 ggatgggggtg tggaagcctg gtgaccaggg cagcagtggg aggctctct cggggtagcc 180
 ttcagggaca ggcaactgcc acttttggtc cccatttccc gcctctcgcc cccaagccc 240
 agacctgagt ttggggggcg agaggcgga aacggggaat gtggcctgag catttcctga 300
 gggcatggcc tggctacctc gacgccagcg ccgagctgag cagtctgcac cctggagcat 360
 ttgttgactg gctgcttgac cagcgcgcct cgcagagggg aaggcagggg cgtcggaggg 420
 gcgcagcgcc ccctgcagcc ggctggagg cggtaggagc ggcgcggaga aggggagatt 480
 ctcgaggag gtggggggcg cgcagtaggg gctgggccc gctctggccc cagggcgcg 540
 ccaccccgcg tgggggcca gccctgatca gagtaggag cgccatctcc tctgggactg 600
 cgaggagcgc ggcggtggcg cactgatggg aggggaccac acggcaacct cggggcgccc 660
 ccccccggt ttctgacacc cggcaggagc ccaggcgag gaggggaggc agctttgcgg 720
 cgccggcgca cgctcgccg actcacgcgg aggtgtgagc ggggcccccg cgcccgcg 780
 tgaccccgag gcccgtgce ccgcgcgcc gggcgccctg gggggcgcg gcggggccgg 840
 ggcgctggca ggcgacgccc tccaccgct ttaaagcctg gggcgcccc ggaccccccc 900
 ccggccccac ccgcggcgcg gggccgccc cctcatgcat atgcaggtgc gcgggtgacg 960
 aatgggcgag cgagctgtca gtctcgttcc gaacttggtg gctgcggtgc cgggagcgcg 1020
 ggcgcgcaga gccgaggccg ggaccgctg cttcaccgc cgccgccgtc gccgccgggt 1080
 gggagccggg ccgggcagcc ggagcgcggc cgccagcgag ccggagctgc cgccgcccct 1140
 gcacgcccgc cgcccaggcc cgcgcgcgc ggcgctgcgc tcgacccgc ccgcgccgc 1200

gccgcccgcg cctctgccgc tgcgctgcc tctgcgggcg ctcgaggggc gggcgggcgc 1260
tgggaggccg gcgcccgcgc tgggagccgg gcgcccgcgc cggcggcgcg gccgggcggg 1320
cgggtcgcgc gggcaatgcg ggcgcagggc cgggggcgcc ttccccggcg gctgctgctg 1380
ctgctggcgc tctgggtgca ggtgagcgcg gcggcggggg cggcgggggt cgcggacggg 1440
gcacaccggg ccgcccctag gggccgggcg ggactgcct ggggccgcgc tggttcgaa 1500
gccctcgagg ctgcgcgcgc cggctggggc tccgggcggg cgcggctggg tgggggcggg 1560
gcggcggggc ctgttcccc acccctggcg cccggcccgc cgaccccggc ccgcgcctcc 1620
ctccgctctc ccgctgcctt atttttaggc ggcgcggccc atgggctatt tcgagctgca 1680
gctgagcgcg ctgcggaacg tgaacgggga gctgctgagc ggcgcctgct gtgacggcga 1740
cggccggaca acgcgcgcgc ggggctgcgc ccacgacgag tgcgacacgt acgtgcgcgt 1800
gtgccttaag gagtaccagg ccaaggtagc gccacgggg ccctgcagct acggccacgg 1860
cgccacgccc gtgctgggcg gcaactcctt ctacctgcgc ccggcgggcg ctgcggggga 1920
ccgagcgcg gcgcggggcc gggccggcg cgaccaggac ccgggcctcg tcgtcatccc 1980
cttcagttc gcctggcccg tacgtgcgt ccacctcgc tgcctcagcc cttccctctc 2040
tctccgcgc ccggccccgc gcgcttcgcg accccaaca cctgcggcg ggtctgcgtg 2100
cgagccgcgc gcgccaggc gggcggggc cggcaggggg cgcgtgctct ggggacttgg 2160
tccgcgcctg gccacgtggg cgcgcgggg ccccggggc accgggagcg gggtcgcggc 2220
gggggcgggg cggcggcgtc ccgcgtgcgc ggcggtgtgc ggcgtgtgc tcgctgcgcc 2280
tgcgcggtgc tgtctgggtg gggaggcgag gcgaggcgcc ccggtcccgc gcaggccgcg 2340
gtggcatgtg cgcagcgcg gctggggctg gtctagggca ggccctgact gagccgcccc 2400
gggcccgtgg ccagcctgc cctgccctgc agtttcctgg atgcctgggg ggcacgggcg 2460
ggcgccgtgg gacctaggcc cgggagagcc taacgcctaa cgcttatgtc ggcagaagcc 2520
cccgatggtg acccaagatc gttcagagac agagatagt gatcctggtg cagtgaacct 2580
ctgtggcact gccctgtttg tgggtttttt tggttttgtt attctggagg ggcagaagct 2640
gagtcggggc tgtctggtct cccctggcag gtggccagtc aggcaggagc cctggcctgg 2700
gcgtgctggg aggaggggtg gtaggggtcc agtgtcactg ggaacaggt actcatccca 2760
gtgggctggc aggtgggtag tggtaggtgg gcaggcccag gcctcgggcg ccttacctca 2820
ttgcctggag cagggccttg cctgggtgcc cagaggtcct tccctgcttg gtcattgtgc 2880
tgggggcctg gaactgggtg agtgcgggaa tgagagcacc atgcagacct gtgatcaggg 2940

agtagatgga tctgggagcc aggaagtggc tccagtcagc aggaggcacc ggagtgtgcc 3000
 cacctgggat cctgggccct gaagtgattg tgagttgagg gcaatccctg ccgagctcac 3060
 gccagttggg cctgccgtgt gtggctccca gtccctgtgt gtacctttgc agccctggct 3120
 ggcagccttg cctgctgccc ccatactcac cgcttccctga gctcccaccc gtggaagctg 3180
 gccacagtct cctctggcca tgtcccaac ccgtgagcac cccgccgagt atcccttgac 3240
 cagggggggc ccagagaggg gaaagtgtcc ccagatgga aaaggcaggg gcgggcatgg 3300
 gagggcccag gcagtttgtga gaagcccagc ccctcgcccc cacggcggtg cagcaggcag 3360
 gtctgagcag ggcccgcagc ctgtcatctg cacctgggcc tgagccagcg tggccccaca 3420
 tcgctacctg aggatgtgtt ttctgctcga gttggcagca gtgggtgtgg gggcagggag 3480
 gtcttgaggg aatgtggcgg gctatcgctg gtccgccctg gctcttcgcc ccgcgggcca 3540
 gccggtcagg tgtgggatgg gaccgggtag gcccttgcc tccctggagt ccgggcactg 3600
 ggtttcgggg ccagctcacc tccctgcctc ttgcttccag ccggttcctc gaatgcccc 3660
 ggagggggca ggcgccctgt ctctgggttg ggggccaggg cagagtcata gctgcgtgtt 3720
 tgggggcagc cctggtctcc tgccatgtgg cctggctgcc gggcgggagc tgtgccgtga 3780
 tgccagcacc ctggtatttg cactcgggcg gcggcagtc ctggccatgc tgccctggct 3840
 tgctgaggtc cagctctgtg cggtagctg aggtgtactt ggctgtgatg ggaaggcaag 3900
 gaccgagttc aggctccctg ggacctgagg aggggtttca gcctggaggc tagggtggca 3960
 tcctgcccag gcccggtggg cttttgggct ccttgagta aagggaatga gagggccttg 4020
 tggaagagga gtgggggagt ctgggctctg cattcgctcc ctccaccccc tgccccctga 4080
 gtgactctcc caccttggtg tctctgctgt tgaccaggc ctggctgggt ggccctctgc 4140
 cccctggcct ggcttcttgt ggccggggtc tgtgtgctat tagtcatgga tctgtgctgg 4200
 tctcgggctc agcttccctc agtgggtggg ccaggggtct tgaatgtgga gaggtggtgg 4260
 accacatgcc agcaggctgc ctggctgccc ctctctcct ggctccaccc ccagacgtcc 4320
 ccaggaggcc ggtgtcagcc tgggttggtt ctgggtgctg gcttgtagct ggcagggtga 4380
 ggccacatto tcccagctgc gtgtgtgcac gcaccccggt tgctctgtag gcatggcagg 4440
 tggatgatga ggtttgggga ggagtagtgt catgctgggg gcagcaggga gctttgctct 4500
 ggggcctggt aggtggcagg ccagggggac acctgctggc tgagggagga gcagggtggt 4560
 ggcagttggc cgtgacctgg gcagccaggg cccaccctc agaggtgcag ctggaagtcg 4620
 tgctgctg gctggcccat ctctggagcc aggagcccag gagcctgcct gccagcgagg 4680
 gtctttcttg ttctgtcttg gcatgtgtgt gctgggctcc agggcagctg tgcggggtgg 4740

tgtggctgga gcatgggtccc cgtgacagat ctgggcttat gaggagaacg ggatgggtga 4800
aggccctgta gatacaggag gtgggcctgg ggctgaccct gcgtctatca gctcaggagg 4860
cctgaggtcc tgggccatca gaagggtga gcttttctca cctgtgaaag gggcacactg 4920
ccgctttttc attgcaggtc tcacgaagtc agatggggct gctggactcc cagctcgggc 4980
tctgcttggtg ccccagccc ggctcccaga cctgtccagt tcctcccctt cccagccttc 5040
cctaccctct cctttgcccc ctaggaggga aggtttttac agagcccacc ccctgcatcc 5100
agccgcccta gggctcaagg tgggccaggc tgagggtctgt gcctggagct acctaagctg 5160
ctcgtggcag gtgtgagggt cagcaccact ctgcttcctg ttttttctga gcttgggctg 5220
gggatgacag ggccctggcc tccccaccct accttcaggg gatcctgtct gcacactggg 5280
gaccaccccc ctcttccca caccttccca gtagggacca ggagagctgg ctggctctggt 5340
atggaatgtg ggcatctggg ttctgtgtgt ggggtggcat cggctctgttc ctctgccat 5400
ggccctgggg cccagagccc tggggagaac tcagggcattg tcgccttgt acattggggg 5460
tctggttcaa agctttggtg tgggggcagg gtggggcatt cagtgccag gcaacacggg 5520
gaccattgga gccagggagg actgcccttg gccagggagg attggagagt gggctggggg 5580
tttgtcgtg gtccctgagg gtgggctgaa gggtaaagc cgcagcacga taggaaggct 5640
gggaggtgga ggggcgggtt ggggagcagg cggcaggcct gggtagggagg ggactgctgc 5700
tctcaggggc cctcctgggc tgctccatgg tgtctttatg aggggagcaa gctaggccag 5760
tgaaggggtg cttgtggagc caggcttcgg cctgagctgc tgctgggtgt ggagtggggg 5820
caggaagaca aggatctgca atcccaggcc ccagccacag tcgctatccc cagaccccag 5880
gcctgagcgg ggtccctgtc cccagaccct aggcctgatt ggagtccctg tccctagacc 5940
ccaggcctga gtggggcccc tatectcagg ccccaggcct gagctgggtc cctgtcccca 6000
gggtcccagga ctgagcaggg tccctgtctg cagacctgag gcctaagcaa ggtccctgtc 6060
cccagacccc agatctgagt gaggtcactg tccccagacc acaggcctga gcggagtccc 6120
tgtcctcaag accacaggcc tgagcggagg ccctgtcccc agaccacagg cctgagcgga 6180
gtccctgtcc ccagaccaca ggctgagcg ggattcctat cccacatcc caggcctgag 6240
caggggtgtg ctggcatcag ttgtaccctg ggctttgtgg cagggtgctag ccggccctgg 6300
ctgccaccgt cttcacgggt ggggacctg gacctagagg ggggtgtgctg gggagtgggg 6360
gtacaccag gcaaggccct ggctggtctc tgggtgtggag catgggtgtg tgtgttcctg 6420
cgtgggatgg gctttggtct gtcctcctg ctgcggccct ggggccaga gccctgggga 6480

tgggtgtttgc cccaccccct tcttccctgc ctcggttgac aatggtggca gaggcctggg 6540
 cctctcagaa gctcaggttt caggaaatgt atctgtgctt ggagctcctg gcgcctgcac 6600
 caagcgctgt gctccgtagg gggcgggagg ctgatgcggg aggccgagga gaagaaacca 6660
 agtcggggcg ttggtggggc agcagggtcta ggaggctgtg ttgtgttggc ctggaccgtg 6720
 cagggccctg' gacctggggg ggccgttagc ggggcagcag ggaggctgtg ttggccttga 6780
 ccgtgcaggg ccctagactt gggttgcctg agttttggga tgctgtagat tggggtacag 6840
 tgggcagtgg ggtgccgtgg acttaggggtg cttggcattt ggagtaccct gggccatgag 6900
 gtgtgctggg ccatgcagtg ccctgggctg ggggtgccct ggacctggag tgccctgagc 6960
 tttggggtgc actgggccat ggggtgcaca aggctgtggg gtgtactgga tctaggggtgc 7020
 cctgggcagg aggtactct gtactttggg tgccttgga ctaggtgtc ctgggcttta 7080
 aggtgccctg gaccttgggg tgtgctgggc catgcagtgc tttggggctc tggggtaccc 7140
 tgggctttgg ggtgccctgg aactggggtg ccctgggtct tggagtatgc tgggccatgc 7200
 agtgccctgg gctgtgggat actctgggct ttggggtgcc ctggacctgg ggtaccctgg 7260
 gctttgaggt gccctggcct ggggtggaac atctattgtc ttgtctgcct gtcctctggc 7320
 ttgtgccact gctgttgccc ctgcctgggg acaggaggag gggtttagac ttagccttga 7380
 ggggttcggg tggggaggag gcaatcagat ggtgggagat gaagttgggc tgcgggtctg 7440
 cttgtgcggt gggggtgggt caggccgggc ttgtagggag aggccttagct gggcctgcag 7500
 ggggtgaagc cttccccctt ggccctcaga gactgggcag gggcatagcc ctgctaggct 7560
 ggccttgagg gagggcctgg gttcctctcc ctgcttgccg gggaacctgg gcagggtgatg 7620
 ggtctctcac ctgtccccag acccccagcc cacacatcgc ctattgcccc tgccagcgcc 7680
 agggccacat cccacatgt cccagccccg ttccatagaag ggcaacatgc ccgccaaccc 7740
 ccgcccacac caggccctat agtccctcct gtgttctagg ggtttggtgt tgacaaaacc 7800
 ctgtcccaga tcgtggcccc ccaggcagga aggacagggg tgagagggtg ctattcgag 7860
 aggaggcaac tgagtcctgg aaggacaggg gtgagagggt gctattcgca gaggaggcaa 7920
 ctgagtcctg gaaggacagg gatgagagggt tgctattcgc agaggaggca actgagtcct 7980
 ggaaggacgg gggtgagagg ttgttattca cagaagaggc aaataagtcc tggaggctgg 8040
 cccctaggga agaaggggag ctgggagagc tggcaggtgg ggtgaggcag gtaccgcccc 8100
 gtcagccagc tcagggttcac tctggatgac ttcttgccat ccagggttag ggaccccagc 8160
 tggcggggcg tgaggccctc tcggcggggc ggcaggcaca cgtccctgcg ggagcaggta 8220
 accggagccc tgggctcagg cgaagggtggc agtaatctta cctgagtggc tggcatgagg 8280

tttcctggga gtcgagagga actccctgct ggccctgaag cccaggtgtg gctgtgccgg 8340
gagaccgggt ggccctggctt ttctctgcct gcccctgggc cagagctgct ctcagaccca 8400
tgctggcccc atcctctgac ctcaactattg ctgcttcctg gtccctgctgg ttcctgtcca 8460
gcggtctacag tgactgttaa agcctgggtg gtcccagtc tcaactcagac ccccaacaac 8520
agacctcact cagaccccca acaacagacc tcaactcagac ccccaacaac agacctcact 8580
cagaccccca acagacctca ctcagacccc caacagacct cactcggacc cccaacaccc 8640
gaacagacct cactcagacc cgcaacagtc acccaacttcg cttagcctca ggaaggaagt 8700
ccgtgggtggg gtctggatct gtggtatgac cccactgtcc ccgtgggcta tgcgttctca 8760
gccctgggc cttcttgttg gctctgccat gcagctcctt cacttctca tgccctgcag 8820
cctcaatctc aatgccacct gttcaaagcc tggcctggcc tttttttttt ttttttgaga 8880
tggagttttg ccctcgttgc ccaggctgga gtgcaatggt gcgatctcg ctcgctgcaa 8940
cctcggcctc ctgggttcag gtgattctcc tgcctcagcc tccagagtag ctgggactac 9000
agacacctgc caccatggct ggctaatttt tataatttta gtagagatga ggattaaccg 9060
tgttgaccag actagtctcg aactcctgac ctcaggtgat ctgcctgcct cagcctctta 9120
aagtgttggg attacaggcg tgagccactg tgacccttg gcctggcctt attggaacaa 9180
cagccccctgc ccctcgttgc tttccccgag ccccgctggc tataggttgc cgtccttgg 9240
ggcagaggca tgcctgctgt acacttgatg tgaacgaagg aaggaaggaa cgaaggagg 9300
agccaaatgc cagacgcctg ggaagcggct ggggtgctca ggtgttaccg ggggtgggga 9360
agggcttggc caggtgcagc tgcgaggggtg gtgctccagg cagatgggtt gataggctgg 9420
ggtgggtggg tgggggtggg caggagcctt gggaacccca aggggtgctct gagctgagag 9480
ggcgtggaca gagtcctggt ggggggtgtg atggagccct ggggggtgtg gatggagctg 9540
acgggggtg tttgtggaca gagcccttgg ggggtgtgga cacagtcctg ggggtggtgt 9600
ggacagagtc ctgggggggtg tggatggagc cctggggggg tatggatgga gcatgttggg 9660
gggtgtggat ggagctctgg ggggggtatg atggagccct ggggggtgtg ggatggagca 9720
tgttgggggg ggtggacaga gctctggggg ggggtgtggac ggagccctgt tgggggtgt 9780
ggatggagca tgttgggggtg tgtggatgga gcatgttggg ggggtgtggat ggaactcggg 9840
gggtgtggat ggagctctgg ggggtatgga tggagccctg ggggggtgtg atggagcatg 9900
ttgggggggtg tggacagagc tctggggggg ggtgtggacg gagcatgttg ggggtgtgtg 9960
atggaactct ggggggtgt ggatggagcc ctgggggggt gtggatggag ctctgggggg 10020

gtgtggatgg agcatgttgc ggggtgtgga tggagccctg gggaggtgat ggagcctgtt 10080
gggggggtgtg gatggaaccc cgttggggga tgtggattga gttctttggg ggtgtggatg 10140
gagctctggg ggggtgtaaac agagctcggc ggggggtgtg gacggagcct tgggagggcat 10200
gtggatggaa ctctggggat tgtctggcgc ctgtaggcag aggtttgcgg gccctgggtga 10260
cctcagggag ccctggagat gggcggggac tgggccccgt ggcctggcgg ggccatggcg 10320
gatgtgggaa aacgggttta aggggagcct aagaggtggg attgagggtc tgttgtcagc 10380
tcgacgtggc tagggagggt tctaggagcg ggttggggat ggccccccac ttccatcctg 10440
tgctcctacc tgggtgagcc tcctcgggcc gtccccgggt gttctgcagg caggggctcg 10500
ggggcggggc cggggttgcc cagctgtgag tgaggcccag ggtcagcagt catgttgggc 10560
cctagtgtgc tgtatttgag ggacagtcgg aggtgtgggg cgggggactg ggtgggggtc 10620
ctggaggctg ggctgggtgt ggctggtagc acgttggtta ggggaggggc tggacgtggg 10680
agtgcagtc tctgagacat cttgggaggc caggcctgtc cttagctgga tgaggccgag 10740
gcactgggac gtgcgtgggg tgggcggcgg gtgaggacca gggaaagggt ggcaggcgtg 10800
gggttgggcc ttgctgggga agtgtggttt tccccagctt agccaggcct tggggctgggt 10860
tggatgggggt gtgctgaggg atggagtgag cctggcctgc ctggacactg cccaacgcag 10920
catccccccg ggggtgggaag ccagcaggcc ctgaggtgac tcagccccag ccccctcctc 10980
tgggccccac ctggaaggag ccagggctgg gctcaggggt caagagcaca ccaggggtag 11040
actgggggggt tcctgggcag tgagggctga gaggctgtgg aatgtgggta cccagtgtctg 11100
ggtagtacag ggcattgtccc ggggggtcca cctgtctgag catgtctgtg agtgacggtc 11160
tccgtgggct gcactaggcg gagcaggggg ccagccctgt ggtctctttg cttggctgac 11220
agcatcgcct gtcgccatgg ctggggtaca agggccagggt ggcccggggg cagagggggc 11280
atagtggcca tgggtctgagg ctgtgctggg cagtcccagg acctcttggc ctcagtttcc 11340
ccaactgtac cgcaagggcc cctcctgcca cctgttctgt gtgagggtg aggtaggtgt 11400
gggtttgcct gtgtgctgta tgccctgcagg acctgagctc cggcctgttg gggcctcttg 11460
ctggggcgccc tgtacttggc caccctgtgc acttgggtga ggccgcagc gtggtgatgg 11520
ggccccacgt tctccccctg ggtcaccccc agtgaggcac caaggggctg tccacaggaa 11580
acgctcgggt cccggctgcc catggggccc ctgtctgtgg cactccagc caggctgccc 11640
tttgcccacc tctccccccg gtctctcttc ctgtgctccg tgctgacttg agccagctca 11700
gggcaggctg ggcctctggc accccaacgg tagggagccc aggccctga gcccgctgg 11760
cctggagggg cagtctccct cccttgagct gggtcatttt tgggtctgca gaggatgtgg 11820

cctgaggatg aggaggggtgg tgggtccctg gctggggagg aagggccaga gcctggcaga 11880
cccaggggca gcgctctgagc cctgggcctt gtcccaccct gaacgaggca ggcagggtgtg 11940
gcctcaggta cctgaccgcg cccccatgt ctgcagcgct cctttaccct catcgtggag 12000
gcctgggact gggacaacga taccaccccg aatgggtgagt gagccctggg ccagggtggca 12060
gtcctctca gcttcagcgt gcctgtggca gggcccagct cctctgtctg cttgggacaa 12120
agccttgctt taccctgagg atcatgtgtg ctgtttccct ttttgctttg gctgccagga 12180
agctctgcca cgtttgggac ttgcagagct gtgcatgcac tctcttcccc agtcctggct 12240
ttgcctatgt tgttctcctc ttgggtgtgc tcttttgggg cccatggcag tgacttagtg 12300
gaggggacac ccttgagtgt gtctctggct ttgtggcccc ctctgcttgt ctgtactgga 12360
gcatggagcc ttggtggccc totccctgag gcaggggctc tgcagggccc tgcaggggta 12420
acgggatgac ttccatgggt gaatgcagaa gcaccacag gccaaaggag cagctcgtgt 12480
gaaggctctg gcaggagcgg gctggctgtg cagggggagc agccggggct gggctcagat 12540
catggaggct ggcaagccac tgagaggaca cgggctccgc ctggcaagct gtggctgcct 12600
tatggagggt gggctgtggg gccaggacac agaccgagga ggagctgcca cgtgaatctg 12660
ggcgtgtcag ggtgacttgg accaggggca gtctgggggt gagaggggct ctcagaagtg 12720
gaggcatggg gttggccaat gggttggagg agggagagcg gggccagggc atcctggctg 12780
ccagcagagt ggaggggctg ttttcagggc agggacggcg gtgggggtgc ccagggtggg 12840
agcagcagtt gtggggaccc cagcggctca gggcaggggt gtttcctgag ggggtggcag 12900
agagacaggt gggctgagtc ccaagcaagg tcgtcagggc tottgacaac gtgagcctgg 12960
agaggctggg gcggccggga cggcccttgg ggagtgggcc agcacagtgt cctcccaggc 13020
cttgccccga ggcgggagag gtggggtctg gaggaccgt tcacctttta ttgtgcaaaa 13080
cgtcgagcct gtgcctaagc gcagggaccg gcatcacgga ctttgcatat cagcgccagc 13140
agctgtggtg cccctggccc ctggtctcct ggtggcttac ttaaagtgag gcttagacag 13200
cgggtcacgg gacctatgcc tgtcttgggg gcctgagggg aggcttgtct taagggtggg 13260
acggtagtg tgtttggcac ttctgggagc aagtcacagc gcaggagagg ggagggcaac 13320
tgagcaccat gtccgtgctg tcgagggtg gacacggcg aggtgggtgc aggtgttga 13380
gcagggtgc aggtgggtgg gcacaggtgt gggacgtgag actcacgccc tggcagcagc 13440
cgtgccttct ctgtggagcc tgtggtctca gcagccctcc ctgcagggcc cctggcccct 13500
agccgggccc cccgaccctc tgcgtttagg gtgggagcgg ggcgaggct tgggtggcgg 13560

agggagagggc ctctcggggc cctgagcttt ctgtagcagc ctggccgggg gccctgccct 13620
ccgtgtgtctg ctgcctgtctg tgccccggcc ttgcagcagc cgcaggcttc tgccccgtcc 13680
ccgttgttcc tggaggaccc ctggccgggc tggtttctct ggcctgtgt gactctgccg 13740
cctccccaag aggagctgtc gatcgagcga gtgtcgcatg ccggcatgat caaccggag 13800
gaccgtgtga agagcctgca cttcagcggc cacgtgggc acctggagct gcagatccgc 13860
gtgcgtgtcg acgagaacta ctacagcgcc acttgcaaca agttctgccg gccccgcaac 13920
gactttttctg gccactacac ctgcgaccag tacggcaaca aggctgcac ggacggctgg 13980
atgggcaagg agtgcaagga aggtgagggg gccgtgggc cgcgtggagg gcagggaggg 14040
cctcgggcag ggccccgggc acaggccttg cggccaggct ggctgcagct gtgcctctcg 14100
ctcctctctg ttgcagctg tgtgtaaaca aggtgtaat ttgctccac ggggatgcac 14160
cgtgcctggg gagtgcaggc gagtgtgccg ccggcccgtc tttgccctcc caacctttgc 14220
cctcacgtcc tctactggcac acacagcctt gctgtcagga gtcgcccga gctggctgga 14280
ggttgggcac acagctgtga gagccgggccc ctgagctcgg gaggtcctt agtgcagtag 14340
gtgcgtgtct gagcatggga tgtgtctgat ggcgccagcc atgtgaggac agtgaggaga 14400
gactggggag gctggctgga cagtccagtc accgaggggc agagacccgg aggctgcaag 14460
ccaccagag atggggcatg ggcagaggac acgtaaccc tgcccatggg gagggggtgg 14520
gcggcgagcg gccggcaagt gacaccagca ggcgaggggc ggcagagcag accagtgggtg 14580
ggagctgagg cctgcaggac cagggacaga ggaaggggct gctggcaggc ttgtagctgg 14640
gcaaggtggg tggaagggct gtggtagctg ttgagtggg aagcaccaga cgggaggtg 14700
tgagggggag gccgtgtgg ggcatgtgg ggtggtggg gaggggccc cgggatgggg 14760
agggggtcag tggaagggg agaggcgcac gggctcctga gacatcctg ggtggagccc 14820
aggggtttgt ggatggattt gatcaagcag gaaggggtgt gagtcaggga gaacccaag 14880
ctgctgagta gcagagccat ggtggcagga ggaatgccac agaggagcag gcggggcccg 14940
ggttagctgg atgtggagag gcgatgcctg ccctgtccct ggagacaccc agaaagctcg 15000
tgggagaggg ctggcctgcg ccacgcggg cctgtgggg gtggcattca ggcggtgacg 15060
ggaaagtggg gaaggcagag aggagggagg ccaaggagca agtcccggct gccacaggctc 15120
aggcggtatg gatgaggagt cagcaagggc ctccacaagg gagtgtccg ggtcttacag 15180
ccaagtccag atggtggagg cctctggacc cagaccagag tgtgggggat ccagccaggg 15240
gggtggcag ctttgcccta gagtggagca gagaagtcag cagggcaacc agaggggctg 15300
gggcccaggg tctgggggtg gcacgggctt cgagccgtgg cgctcactgt gcgtgagcaa 15360

gctggggagc ccgagagagg ggcgcgagcg ggtggagaga cagcaggtgg aggtgagcac 15420
cgccctccag ccagccttgg attgcagggg tcccaggacc tccctctgtg gagtgggttt 15480
gcctccatgg gacgaggaca ctggggcaca gagagcctac tgatttcccc agggtcacac 15540
agcgtggcgt tttggagagg agtcggggag tttgggaacc agctgagttg ggagccaagg 15600
tggggaggtg ggtgaccctt ccacaggccc cacggttag tggcctggag ggtacagtga 15660
ggagctttcc cggccagtcc cagagcgggg aggcaagcag ggctggggcc gccaccccg 15720
tcacttgac acacagggat tcccggcagg ttgagcgagt cccaagtcag ctcaaaaagt 15780
gcaacaaggt ggacctggct tgggcagatg tagatgtaga tctacgggag tcggcccccac 15840
tcaccctcgc ctggcccagt gtgcatcaca caacctggat ggcagtgccca ccctccctgg 15900
atggctgctg gctggcagct tgaatgtcac accaaggctg gaggaaggca gcagagaagt 15960
tggccatccc tgccctttac ccgcaggaag atgagccgga gtctgggggg cctggtgggt 16020
gggggcagta ggtgagctcc gcctgcccct ctgtctggcc ctgtcgggga ggcccagctg 16080
ttgtgacag cctcggtcca ggttccagtg caggacgccc cccacccgga tgctgcggag 16140
atggccatgc ctctctgccg ccgcctctcc agggccctgg ggctgctggc tggggaaacc 16200
aggaggtggg ggcctggtgt gggctgccct gccagggtc gagagcacgc ccttgggacc 16260
cacgaggtct gggctctgag cccggctgtg gccgctctct ggccgatgac ccaaggtgtg 16320
tcacagcccc gccctgagcc tgggtctctg tgtctgtgga ggagggattc taggcgggat 16380
gtgaggccac ccacgcggac cactgtgcat gctgggctgg atactggaga cacgttcttc 16440
ccggcctcag tttccccatt tgtggcagct gaactgggct gataggcctt cgggtgctggc 16500
tgtgtggctt gagggcggtc caggaagggc cgtggttctt tccttttaca aaaataaagt 16560
gtggcggtg ccggtgtgga agtgacgtg cctggatgac attcccgctc tgaggaccg 16620
gagagttcta ggaaggggcc cccgggagtc ccggcagggc ctggatggca gcctgctgag 16680
ccttggggtc gttgcaggct ctctcccctg acggaggcac cctcaagtca ggccatgttc 16740
taccctggcc acctgcctc tcctggggga ctccaagac aggacgttg ccgatagcct 16800
ggggcagggc gagtccctgg ggttgtgtcc tggggggtgc agctgggggt gcagctggag 16860
ctcctgcaga atcaggaact accctgggca gggctggccc aggccagcct gtgggcctca 16920
gtagcccat ctgtgagatg ggtaccttgt gggactttac tgggagcgag cgaaatgact 16980
gcctttgagg tgggggcgag ggcacgtgct gtgcccaggg ccacatggcc gaggcagagc 17040
caggagtgtc cccctgctgc ccgctggcct acccagcccc tgggtgcctc cggccctggc 17100

agcaccttgt gagtccgagc cggcattctc atccccgggg tcccggcagg gccttccttt 17160
cctgggtgcct gctctcgggg cccagctcac ggggtgaatcc caaaatagct caggaggag 17220
tgacgggaca gctggggctg accgtcggca gccagcggcc gggaatgcc gtgacagtgg 17280
ggctggccgg cagggtcga acccctgcct ggctggggct gctccagttc aaaggcctga 17340
ggccgcccgc cggccctggg tgtggcgtgg gtgactgtgc ctggctcccc tgccaccctt 17400
tcaggcacca cagctcactg ggtcttgccg ccctcctcct tccccagggt gcagctacgg 17460
ctggcaaggg aggttctgcg atgagtgtgt cccctacccc ggctgcgtgc atggcagttg 17520
tgtggagccc tggcagtga actgtgagac caactggggc ggctgtctct gtgacaaagg 17580
tagtggtagg gggcggcagg cctaattgctc tgccatcgaa gtgtgggttg tgggggagcg 17640
ggggggccggc ttttcccctg agcatccac ccctgcccc agacctgaac tactgtggca 17700
gccaccaccc ctgcaccaac ggaggcacgt gcatcaacgc cgagcctgac cagtaccgct 17760
gcacctgcc tgacggctac tcgggcagga actgtgagaa gggtagctgg ggggctggcc 17820
accocaaattc tggccaggca gggactggtt ccctggggag ccggtcaggc cccatccctc 17880
tggcgtcctg tgtggtgggc ccctgacccc cagcttggga acctgtgggc ttggggagga 17940
gtgcttgttg aaagctgggg gcctggctgc cagctctgcc ccctccccgc ggttctacag 18000
ctgagcacgc ctgcacctcc aaccctgtg ccaacggggg ctcttgccat gaggtgccgt 18060
ccggcttcga atgccactgc ccatggggct ggagcggggc cacctgtgcc cttggtgagt 18120
gtctgcacgt gagtagggga ctctgccta gtatcagtgg gggctctggga gtggggcaac 18180
tcgctgggga tggggtgcag tggtaagtc cacacgtgtg gctgcggctg gcttggcgag 18240
gacaaatggc aggaagacc aggttgcag cgccacctgc ccatggggac cttattccca 18300
cggtcacac tgccagggcc ccaccttct ccacctctg cagacatga tgagtgtgt 18360
togaaccgt gtgcggccgg tggcacctgt gtggaccagg tggacggctt tgagtgcac 18420
tgccccgagc agtgggtggg ggccacctgc cagctgggta agggctccga gcgagtgcac 18480
gggaacgtgg gccgcgcatg cgggtgcgg gggctgctgg ggctgcgggg gctgctgggg 18540
ctgctggggc tgctgggctg cgggtgccag gtgcccgtgc tgcagggggc aggcagggcc 18600
cgagccccac ggctcccacc ttgtctcttt cacagacgcc aatgagtgtg aagggaagcc 18660
atgccttaac gctttttctt gcaaaaacct gattggcggc tattactgtg attgcatccc 18720
gggtggaag ggcataact gccatatcag tcagtatggg ggggtgggcgc cggcgggtgg 18780
gccgaggcac atgggacccc gcctotgacc ctgctcctct gccccagac gtcaacgact 18840
gtcgcgggca gtgtcagcat gggggcacct gcaaggtgag gcggggccag gaggtgtgt 18900

ggcgtgggtg ctgcggggcc gtcaggggtgc ctgcgggacg ctcacctggc tggcccgccc 18960
aggacctggt gaacgggtac cagtgtgtgt gccacgggg cttcggaggc cggcattgcg 19020
agctggaacg agacgagtgt gccagcagcc cctgccacag cggcggcctc tgcgaggacc 19080
tggccgacgg cttccactgc cactgcccc agggttctc cgggcctctc tgtgaggtga 19140
ggtctgcctg gtcacctgc cccacctgct gctctgggag ctgtagggca ggcctcgtcc 19200
cctgaccatg gggcctgagt gaccagggg tgctgcaggg gaagttgtcc ccaaggcgtc 19260
ccaggctcag ctctccactg ggtgccaggg gggcaggcgg ggctgtcaca ggtcaccagg 19320
cttggccccc tgtggccatt gcttgttgtg atgggtttcc tggtagcctg ggctaggagc 19380
ccccgggctg ctggctgccc aggcctatct gtccatctgt gcaactccctc gggactggag 19440
ggcagggggc tctggtgggc agagcacatg gggtaggggtg ggtgcctgat ggtggagagg 19500
tatacacctg tcataggtga gtccctgggtc ggagtgggca tctctctcag ggctgatgct 19560
ctgcctccc tctgaccatc tgttggtact ggaccccc caccacctc cctaccaccc 19620
tcggccgccc acgatcctgc cctggccttg gtgcagagga tgggcctcct gtccagaggg 19680
cttcttgggg ccaggggcag ggggtctgacc tcaggacctg caagcatggc agtggctggc 19740
cctggaaaag acccacagtc ttggctctga gggtagggcag gcagtgtgtg aggggctcag 19800
gagctgtcct tcctgccagc agcagggggc aaggccacac tcctcccgag ggacagtgag 19860
gaagctgggc tgcagtggag gtgggggtgg gggccacag gtatctgcgt tcagctaagg 19920
cctgggcagt ctcagggtggg caggggtctt gggctctggc tggcactgtt agggccaggg 19980
cggagggggc tgggggtccc cagggatcta ccttcgtatg gacagaggcc tggcctgtgt 20040
tcccggcctg ggcctgggccc taggtctctca caggcacccc ccacctgca ggtggatgtc 20100
gacctttgtg agccaagccc ctgccggaac ggcgtcgct gctataacct ggagggtgac 20160
tattactgcg cctgccctga tgactttggt ggcaagaact gctccgtgcc ccgcgagccg 20220
tgccctggcg gggcctgcag aggtgctggg tgcggcattg ggtggtgggg gaggtggtgg 20280
ggcagggggc ggcctgactc ctgactgtac tgctgccat agtgatcgat ggctgcgggt 20340
cagacgcggg gcctgggatg cctggcacag cagcctccgg cgtgtgtggc ccccatggac 20400
gctgcgtcag ccagccaggg ggcaactttt cctgcatctg tgacagtggc tttactggca 20460
cctactgcc a tgagagtgag tgccacgaa cggcgggctg gtggtggggc tgggctggcc 20520
tgaggccctg gctaccccc ctgcctctg cagacattga cgactgcctg ggccagccct 20580
gccgcaatgg gggcacatgc atcgatgagg tggacgcctt ccgctgcttc tgccccagcg 20640

gctgggaggg cgagctctgc gacaccagtg agtggtccag caccgcacca cacggcctgt 20700
gcctccaccc ctgtggggccc cttatcacc tgagatggac cgctgtctgg gtgcggcagg 20760
ccccgtaccc agaaaggcct ggccaggggg tgctgccacc atgggggtgga gtcccaggct 20820
gcccccatgc ccgaggccag ccccccggc ccgacgtcc tccccgccc ctctctgtcc 20880
tcacctggcc cagctccagt gcttctctcc ccgggaagcc ctccctgagc gccggtgacc 20940
ccccgcccgc tgaccggcgt cctcgcccc agatcccaac gactgccttc ccgatccctg 21000
ccacagccgc ggccgctgct acgacctggc caatgacttc tactgtgcgt gcgacgacgg 21060
ctggaagggc aagacctgcc actcacgtga gtgtccgcag gccctggccg cctggggctg 21120
cccccaggac cctggccctg gcggtctggg gcctgcctgc tgagcggccc atgtgccaac 21180
aggcgagtgc cagtgcgatg cctacacctg cagcaacggt ggccacctgt acgacagcgg 21240
cgacaccttc cgctgcgcct gcccccccg ctggaagggc agcacctgcg ccgtcgggtga 21300
ggagcccccg ctgcctctgc gaccgcggg catatgccct ccaggccacc gctccctcgg 21360
gcgcgatggg ccgaggggtc ttttttgagg gccacacctg ccacctgcc cctgccccct 21420
gcccccggt ctgtctgcc tgtctgggtt gggggcgcg tatggagacc cagggccagc 21480
ccagggccag gtgagacgt cctctctct cctctcttta cagccaagaa cagcagctgc 21540
ctgccaacc cctgtgtgaa tgggtggcacc tgcgtgggca gcggggcctc cttctctgc 21600
atctgccggg acggctggga gggctgtact tgcactcaca gtgagtgtgg gaggggtgtg 21660
ggcgggggccc gcttctctcc accagatga catccctgcc cccgactgc ccccagctcc 21720
cttctgccag cccctcccc tgctgcccct gccccagca aaaggcacc tccttgatga 21780
ccctccccag cccacagcc tgatcacgcc aagccagcct ggacagtgcc tggcacgctt 21840
gggggggtgg tactgatccc ctgcgttctc ttctccaaa ccagatacca acgactgcaa 21900
ccctctgcct tgggtgagtgg caccctgggg gccacagcag ggggtgggtg gacttggcat 21960
accacggggg gccacctgat gccaccctc tgcctctgcag ctacaatggg ggcatctgtg 22020
ttgacggcgt caactggttc cgctgcgagt gtgcacctgg cttcgcgggg cctgactgcc 22080
gcatcagtga gtggccagac agccccagcc ctgggagccc ctgagcccag ccgcggtgtc 22140
aggagtctgg ggacatcaac gtccacgtcc cttgaagggc agtgtggcca caactacttc 22200
ctgcctctct tctgagcctc agtttcccca catgtctgtg ccctgtgggg ttctgtctgt 22260
ataccctgcc aagtgattaa gtggggagcc ccagcctggg ggaccagtcc ggggcccagg 22320
gagctgtggg ggttgagcgt tgcagcctga cgtgggctcc tctgtggccg cagggctgtt 22380
gtccctgggt gttggcccag ctgtctgtcc agcaccctt ggctgggtcc acgcagcagc 22440

tggggctaata ccaggatggg acaggccac tgcagaagca gacggaggag ggtgctgttg 22500
ggccagggtc aggtcgggct caggaaggcc tcaggcaggc agcagcttg gctcgggggc 22560
aggggctgct cctcattgtc ctggggcttg cgcctgtgtg ccactggctc cccgctgccc 22620
taggccatgc cggctcctgog gtggggcgttg gcctcactgc actgagcagc ggtggctctc 22680
cctgcagaca tcgacgagtg ccagtcctcg ccctgtgcct acggggccac gtgtgtggat 22740
gagatcaacg ggtatcgtg tagctgccc cccggccgag ccggcccccgt gtgccaggaa 22800
ggtaggcccc gtgtgattgc cctggggttg ggcggggttg ggggcatggg tgacaccag 22860
ccccgagggc cagatgccc ctgtgaccc tcgagcccct tctcccaca gtgatcgggt 22920
tcgggagatc ctgtgtgtcc cggggcactc cgttcccaca cggaagctcc tgggtggaag 22980
actgcaacag ctgccgtgc ctggatggcc gcctgactg cagcaagggt agggcagccc 23040
gtgagccgcc ctgccctacc cgaggctggg gcaogctgac cctggccact ctgtgagatc 23100
aggaggcggg tgctggggtc cggatggact gagagccgtc tgccctcagg gacaccag 23160
gaggcgagag ctgagccagg ccccatgctt cgatgtgcag ttgggaaaac aggcctggtc 23220
tgggtcctgc cttgctccgc ctgcccttct tgatgtcgag cttggcctgc ctccctggga 23280
gccctgggta gggggtgggc tgggccctgg ggctcacaga cttgggcggt gtccctcctt 23340
ggcatggggc ccgtgcctgc ctgtgggttc tcatctgtgt gcctgcatct gaccctcctg 23400
tgcgcctgcg cctgaccctc ctgtgcgtgc ctgccagggt gtggtgcgga tgggaagcctt 23460
gtctgctggc cggccagccc gaggccctga gcgccagtg cccactgggg caaagggtgc 23520
tggagaaggc ccaggccag tgtctgcgac caccctgtga ggcctggggg gagtgcggcg 23580
cagaagagcc accgagcacc cctgcctgc cacgctccgg ccacctggac aataactgtg 23640
ccgcctcac cttgcatttc aaccgtgacc acgtgcccc ggtgaggggc ctggtggcat 23700
ctgagcttg agaggccaca cgccggcatc tgctcgtggc atggcgaaag cctagccccg 23760
cagggcaggg aggccctggg tggctgagca gactcactct tggtcacaga gagtggccct 23820
gtggggtcag atgagagggg cattgggcct ggtgctgggt ggaggtggca gaggaggctg 23880
ggagagcagc cagctggggg tgccctgttg tccagctgcc ctgagggcct ggactgacgg 23940
cgccatggct gcctggcccc agctcttggg ctgcagctcc gtgggcagtt ttgccctggc 24000
ctaggacca cctttgcctg ctgtgtgctt ggagctgggc ccctgtctcc caggaggggc 24060
tcagaactgg aggagacca ctgtaccccg ccctgcctct ccttcccca ctggcctgca 24120
ggtggagctg ggtccgcctt gaggatgggc ggggtgggcac cgtcactcct gcctcctggg 24180

atagggcaca gccgggtggg aagctgcccc ccagggccct tggcatcctt gctgtgctct 24240
cctgggcggg ctgtagggtg tgtcccacgt gtaccacacag cgccagtcca gggatgtagg 24300
tgtcaggttc acggccctgc cctgcccacg cactgcctgt ctctgcccag ggcaccacgg 24360
tgggcgccat ttgctccggg atccgctccc tgccagccac aagggtgtg gcaagggacc 24420
gcctgctggg gttgctttgc gaccgggctt cctcgggggc cagtgtgtg gaggtggccg 24480
tggtgagtgc ccagtgggga gcagcacctg ggtgggccct gggccccgta ctatgcagg 24540
cctggctatg ctggacagag gctctggcga ggctagtcct ggtgcggaag gactgcgggc 24600
aggcctgtct ccctgcggcc cctcgtgtc catgccgcag acccgtggaa ctgctccctg 24660
ggcctggcca gcatgaggga gatgcagggc tgtggtgtg agcccgttc ccctgcagct 24720
gcatcctcgc ccgggtccct gctctgtttt tgtctctgtg tccctacgtc acaggcagca 24780
ggagagtccg tgggcttagt ctgccctggg aggcctgctt tgggactggc acctgccctg 24840
gacctggggg gtgtcagatg tgaatggata ccaaggggtg cgggtgagac tggggtggag 24900
acatgcccg agaggggagg gaatgttctg gaacatggtg ggtgggtgtg cagagcagtg 24960
ggtgtggcca tggcacagtg tggctggtg aggccatggc caggcacagg aaggacgtgc 25020
agtgttttg tgccctgagg ccgcagagg ggtgggggac atggatgggt gctgctgggt 25080
gatggaagg cagtaggggc aggggaagat gtaagaagt tgccagcaca ggtcagggcg 25140
ccatcaggga tgtggtggag gcaggggcac agccccgggt tgctgtggcc tcgtgaaggc 25200
actaggtttg tggtgccct ggggtgtggc ccataggtg ggtgggggc tgggaactga 25260
caagaaggga tggccatcac ggagcagggt tcagcgaatg gggccacaca cctccccaac 25320
tcaactgcctg gtggcgagg cccaccgca ggaccccggt ctctcctgtg tgcccgagcg 25380
gggacaccct ccacccctcc acttcccccc acccctcact gcctgctggg gaggtcccca 25440
ccgcaggacc ctgggtgtgc ccgtgcgcc ggatggggac atcctccacc cctccccttc 25500
ccccactgc tcgtgcctg gtggtgagg cccacacct caggaccctg ggctctcctg 25560
tgtgcccga tggggacagc ctccaccct ccactcctcc ccccgctact cccactcac 25620
tgctgggtg tgaagtgcgc actgcaggac cccgggtct cgtctccgt gcgcccacct 25680
tgctccagt tggccagggc ctcaagtgt ggggcaggct gctgggagcc tggagccctc 25740
gagccatccc caaatgccc ttctttgccc cagtccttca gccctgccag ggacctgcct 25800
gacagcagcc tgatccagg cggggccac gccatcgtg ccgcatcac ccagcggggg 25860
aacagctcac tgctcctggc tgtcaccgag gtcaagggtg agacggtgt tacgggcggc 25920
tcttcacag gtaagcgcg gaggtgggccc cctgggaagg caccaggcag gcaactcagg 25980

cattgggcac agagccggcc gatcctgccg atcctgccag ccaccaggaa cacagaagtc 26040
cctggcacct gctgccccag cggcccagcc ccacaacctg accttcccag cccccgtcct 26100
gggaccctcc ccacgagcca gcaaccggag ggtggggccc ggccgcctgg cccgcagggc 26160
cctcccaggc ctgggtgtgt ggctagtgc cgcaggtgc ccaggcctca ttgcccaccg 26220
gctcttctcc ccgggtccca ggtctgctgg tgcctgtgct gtgtggtgcc ttcagcgtgc 26280
tgtggctggc gtgctgggtc ctgtgctgt ggtggacacg caagcgcagg aaagagcggg 26340
agaggagccg gctgccgcgg gaggagagcg ccaacaacca gtgggccccg ctcaacccca 26400
tccgcaacc cattgagcgg cgggggggccc acaaggacgt gctctaccag tgcaagaact 26460
tcacgccgcc gccgcgcagg ggggacgagg cgctgcccg gccggccggc cacgcggccg 26520
tcaggaggga tgaggaggac gaggatctgg gccgcggtga ggaggactcc ctggaggcgg 26580
agaagttcct ctcacacaaa ttcaccaaag atcctggccg ctgcgccggg aggccggccc 26640
actgggcctc agggcccaaa gtggacaacc gcgcggtcag gagcatcaat gaggcccgt 26700
acgccggcaa ggagtagggg cggctgccag ctgggcccgg acccagggcc ctcggtggga 26760
gccatgccgt ctgccggacc cggaggccga ggccatgtgc atagtttctt tattttgtgt 26820
aaaaaaacca caaaaaaca aaaccaaagt tttattttct acgtttcttt aaccttgtat 26880
aaattattca gtaactgtca ggctgaaaac aatggagtat tctcgatag ttgctatttt 26940
tgtaaagttt ccgtgcgtgg cactcgctgt atgaaaggag agagcaaagg gtgtctgcgt 27000
cgtcaccaa tctagcgtt tgttaccaga ggttggtcac tgtttacaga atcttccttt 27060
tattcctcac tcgggtttct ctgtggctcc aggcacaagt gccggtgaga cccatggctg 27120
tgttggtgtg gcccatggct gttggtggga cccgtggctg atggtgtggc ctgtggctgt 27180
cgggtgggact cgtggctgtc aatgggacct gtggctgtcg gtgggacctt cggtggtcgg 27240
tgggaccctg gttattgatg tggccctggc tgccggcacg gccgtggct gttgacgcac 27300
ctgtggttgt tagtggggcc tgaggtcac gccgtggccc aaggccggca ggtcaacctc 27360
gcgcttgctg gccagtcac cctgcctgcc gtctgtgctt cctcctgcc agaacgcccg 27420
ctocagcgat ctctccactg tgctttcaga agtgcccttc ctgctgcgca gttctcccat 27480
cctgggacgg cggcagtatt gaagctcgtg acaagtgcct tcacacagac ccctcgcaac 27540
tgtccacgcg tgccgtggca ccaggcgtg ccacctgcc gggccggcc gccctcctc 27600
gtgaaagtgc atttttgtaa atgtgtacat attaaaggaa gcactctgta tatttgattg 27660
aataatgcc ccatccggc ctcccttgtt ctttcggtgc tgtccctttt gtattgagag 27720

31

tgagggttggg ggagagccac gccggcagag aggcttgggg cagtggggca cgtgctgggt 27780
 attggcccac gtggctgtgg tggctgtaga gggcgagacg gttctgttga gtcggggcct 27840
 gccagggcct cgaatgcgtt ggcattgcaa ggtggtggat gcaggtttgg ccaaaacctt 27900
 cctgggaatg gggagggggg tgtctaggtg cctggcaccg gaccctgact aaaacagctg 27960
 aaaacagttt tataaaatag tataaaattg cttaccacg 28000

<210> 12
 <211> 419
 <212> DNA
 <213> Homo sapiens

<400> 12
 tgcggccgcc ccttctcgtg aaagtgcatt tttgtaaagtg tgtacatatt aaaggaagca 60
 ctctgtatat ttgattgaat aatgccacca ttccggcctc ccttgttctt tcggtgctgt 120
 cccttttgta ttgagagtga ggttggggga gagccacgcc ggcacatagg cttggggcag 180
 tggggcacgt gctgggtatt ggcccacgtg gctgtggtgg ctgtataggg cgagaccgat 240
 ctgttgagtc ggggcctgcc acggcctcga atgcgttggc atgccaagggt ggtggatgca 300
 ggtttggcct aaaccttcct gagaatgggg acgggggtgg atctggaatt ggcattgatta 360
 caaactactc tgcaattctt cctctcccca attaagggtgt ctctcttgaa ctgattgaa 419

<210> 13
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Antisense Oligonucleotide

<400> 13
 tacaaaaatg cactttcacg 20

<210> 14
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Antisense Oligonucleotide

<400> 14
 tggcattatt caatcaaata 20

<210> 15
 <211> 20
 <212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 15

gcgcacctgc atatgcatga

20

<210> 16

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 16

gaaatagccc atgggccgcg

20

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 17

cagctgcagc tcgaaatagc

20

<210> 18

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 18

gcagcgcgct cagctgcagc

20

<210> 19

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 19

gcagctcccc gttcacgttc

20

<210> 20

<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 20
gctcagcagc tccccgttca 20

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 21
tggtactcct taaggcacac 20

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 22
caccttggcc tggtactcct 20

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 23
gccgtagctg cagggccccg 20

<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 24
ggcaggtaga aggagttgcc 20

<210> 25

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 25
gacgaggccc gggtcctggt 20

<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 26
ttgtcccagt cccaggcctc 20

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 27
aggctcttcc agcggtcctc 20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 28
gctgaagtgc aggctcttcc 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 29
ccacgtggcc gctgaagtgc 20

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 30
ggccggcaga acttggtgca 20

<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 31
ttgccgtact ggtcgcaggt 20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 32
gcaggccttg ttgccgtact 20

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 33
catccagccg tccatgcagg 20

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 34
ccccgtgga gcaaattaca 20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 35
gtagctgcac ctgcactccc 20

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 36
cagttgcact gccagggtc 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 37
gttgggtotca cagttgcact 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 38
ccgccccagt tgggtctcaca 20

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 39
gcaggccgcc ccagttggtc 20

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 40
acagagcagg ccgccccagt 20

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 41
ttgtcacaga gcaggccgcc 20

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 42
ttcaggtctt tgtcacagag 20

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 43
gccacagtag ttcaggtctt 20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 44

ggtgggtggct gccacagtag

20

<210> 45

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 45

gaggtgcagg cgtgctcagc

20

<210> 46

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 46

cccttcacac tcattggcgt

20

<210> 47

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 47

aggtttttgc aagaaaaagc

20

<210> 48

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 48

cacagtaata gccgccaatc

20

<210> 49

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 49
gatgcccttc cagcccgga 20

<210> 50
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 50
gcaggtgccc ccatgctgac 20

<210> 51
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 51
ccaggtcctt gcaggtgccc 20

<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 52
gggcacacac actggtaccc 20

<210> 53
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 53
gggctgctgg cacacttgctc 20

<210> 54
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 54
gagcagttct tgccaccaaa 20

<210> 55
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 55
ccgcagccat cgatcactct 20

<210> 56
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 56
gtgcccccat tgcggcaggg 20

<210> 57
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 57
agaagtcatt gaccaggtcg 20

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 58
cacagtagaa gtcattgacc 20

<210> 59
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 59

cgtgagtggc aggtcttgcc

20

<210> 60

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 60

ctggaactcg cgtgagtggc

20

<210> 61

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 61

ccgttgctgc aggtgtaggc

20

<210> 62

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 62

caggtgccac cgttgctgca

20

<210> 63

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 63

cgtagcaggt gccaccgttg

20

<210> 64

<211> 20

<212> DNA

<213> Artificial Sequence

<220> .
<223> Antisense Oligonucleotide

<400> 64
ttgggcaggc agctgctggt 20

<210> 65
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 65
agggttgcag tcgttggtat 20

<210> 66
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 66
gcagcggaac cagttgacgc 20

<210> 67
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 67
ccgtaggcac agggcgagga 20

<210> 68
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 68
ttgatctcat ccacacacgt 20

<210> 69
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 69
ggtgggcagc tacagcgata 20

<210> 70
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 70
gcagctgttg cagtcttcca 20

<210> 71
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 71
ccaggcagcg gcagctgttg 20

<210> 72
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 72
ctgctgtcag gcaggccct 20

<210> 73
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 73
ctggatcagg ctgctgtcag 20

<210> 74
<211> 20
<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 74

tccaccttga cctcgggtgac

20

<210> 75

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 75

gcgcggttgt ccactttggg

20

<210> 76

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 76

ccctactcct tgccggcgta

20

<210> 77

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 77

gacggcatgg ctcccaccga

20

<210> 78

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 78

gaataattta tacaaggtta

20

<210> 79

<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 79
aatactccat tgttttcagc 20

<210> 80
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 80
tcatacagcg agtgccacgc 20

<210> 81
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 81
caccctttgc tctctccttt 20

<210> 82
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 82
cacccggcact ttggcctgga 20

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 83
gggtcccacc aacagccatg 20

<210> 84

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 84
gaagggcact tctgaaagca 20

<210> 85
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 85
acagttccga gggttctgtg 20

<210> 86
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 86
ctggctggat cccccacact 20

<210> 87
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 87
gggagcactc ctggctctgc 20

<210> 88
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 88
ccatactgac tgatatggca 20

<210> 89
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 89
cgacatccac ctgcaggggtg 20

<210> 90
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 90
tggcaggccc cgactcaaca 20

<210> 91
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<220>
<221> misc_feature
<222> (1)..(20)
<223> n=a, c, g, or t

<400> 91
nnnnnnnnnnnnnnnnnnnnnnnnnnnnnn